NCCN Breast Cancer Risk Reduction Panel Members

Summary of the Guidelines Updates

Familial Risk Assessment (BRISK-1)
Elements of Risk, Risk Assessment, and Risk Management (BRISK-3)
Risk-Reducing Therapy Not Desired: Risk Assessment and Screening/Follow-up (BRISK-4)
Risk-Reducing Therapy Desired: Baseline Assessment, Risk-Reducing Intervention, and Follow-up (BRISK-5 and BRISK-6)
Clinical Scenarios and Management While on Risk-Reducing Therapy (BRISK-7)

Components of Risk/Benefit Assessment and Counseling (BRISK-A)
Breast Cancer Risk-Reducing Agents (BRISK-B)

Clinical Trials: NCCN believes that the best management for any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/clinicians.aspx.

NCCN Categories of Evidence and Consensus: All recommendations are category 2A unless otherwise indicated.

See NCCN Categories of Evidence and Consensus.
Updates in Version 1.2019 of the NCCN Guidelines for Breast Cancer Risk Reduction from Version 2.2018 include:

**BRISK-1**
- This page has been significantly edited, sending the reader to the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.

**BRISK-2**
1st column, 3rd bullet:
- Clarified lifetime risk of >20% to "≥20%" (Also for BRISK-4).

**BRISK-3**
- Modified the following: "Breast cancer risk assessment (eg, modified Gail Model for women ≥35 y of age)"

**BRISK-3A**
- "h" modified: "The management for women with DCIS and invasive breast cancer is available in the NCCN Guidelines for Breast Cancer"
- "n" modified: "There are limitations to all of the models for risk assessment. The modified Gail Model (NCI Breast Cancer Risk Assessment Tool) is a computer-based version and may be obtained through the NCI website (http://www.cancer.gov/bcrisktool/Default.aspx). There are circumstances in which the Gail Model underestimates risk for development of breast cancer, for instance, BRCA1/2 carriers and those with a strong family history of breast cancer or family history of ovarian cancer in the maternal or paternal family lineage or non-white women or women with atypical hyperplasia, making them appear to be ineligible for risk-reducing therapy. The Claus, BRCAPRO, Tyrer-Cuzick, and BOADICEA models may be particularly helpful in determining risk for breast cancer in women with a strong family history of breast, ovarian, or other cancers. *Tyrer-Cuzick overestimates risk in women with atypical hyperplasia and dense breasts.*"

**BRISK-7**
- The following clinical scenario has been deleted: "Consider discontinuing tamoxifen or raloxifene prior to elective surgery."

**BRISK-A**

**Healthy lifestyle**
- Deleted the following: "Limit alcohol consumption to less than 1 drink per day (serving equals: 1 ounce of liquor, 6 ounces of wine, or 8 ounces of beer)."
- Added the following: "*Alcoholic drinks increase the risk for breast cancer; limit alcohol consumption.*"
- Exercise
  - Added the following: "*For premenopausal women, be vigorously physically active.*"
  - Added the following: "*For postmenopausal women, be at least moderately physically active. Be active daily, taking part each week in at least 150 minutes of moderate-intensity, aerobic physical activity or at least 75 minutes of vigorous, aerobic physical activity (or a combination).*"
- Weight control
  - Added the following: "*For postmenopausal women, be a healthy weight and avoid weight gain.*"
FAMILIAL RISK ASSESSMENT\textsuperscript{a}

Familial/genetic factors
- Known genetic predisposition to breast cancer (\textit{BRCA1/2, p53, PTEN,}
  or other gene mutation)

Woman meets one or more of the familial/genetic risk criteria outlined in NCCN Guidelines for Genetic/Familial Assessment Breast and Ovarian

Referral to genetic counselor or a similarly trained professional recommended\textsuperscript{c}

\textsuperscript{a}See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.
\textsuperscript{b}The criteria for further genetic risk assessment and genetic testing are not identical. For the purposes of these guidelines, invasive and ductal carcinoma in situ breast cancers should be included. The maternal and paternal sides of the family should be considered independently for familial patterns of cancer.
\textsuperscript{c}For further details regarding the nuances of genetic counseling and testing, see NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian--BR/OV-A.
ADDITIONAL RISK ASSESSMENT

Yes

Risk-reducing counseling

Woman does not desire risk-reducing therapy (See BRISK-4)

Woman desires risk-reducing therapy (See BRISK-5)

and

Life expectancy ≥10 y

No

(See BRISK-3)

• Known genetic predisposition
or
• Pedigree suggestive of genetic predisposition
or
• Lifetime risk ≥20% based on models largely dependent on family history
and
Life expectancy ≥10 y

See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.

Woman meets one or more of the familial risk criteria (See BRISK-1).

Risk models that are largely dependent on family history (eg, Claus, BRCAPRO, BOADICEA, Tyrer-Cuzick).

See life expectancy calculator (www.eprognosis.com). For a reference point, the life expectancy of the average 78-year-old woman in the United States is 10.2 years. (See NCCN Guidelines for Older Adult Oncology).

See Components of Risk/Benefit Assessment and Counseling (BRISK-A).

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## Elements of Risk

**Elements that increase risk**
- Family history
- Increasing age
- Ethnicity/race
- Lifestyle factors
  - Increased body mass index (BMI)
  - Alcohol consumption
  - Current or prior estrogen and progesterone hormone therapy
- Reproductive history
  - Younger age at menarche
  - Nulliparity/Lower parity
  - Older age at first live birth
  - Older age at menopause
- Other
  - History of lobular carcinoma in situ (LCIS)
  - Atypical hyperplasia (ductal and lobular)
  - Flat epithelial atypia (FEA)
  - Number of prior breast biopsies
    - Procedure done with the intent to diagnose cancer; multiple biopsies (needle/excision) of the same lesion are scored as one biopsy.
  - Mammographic breast density
  - Prior thoracic radiation therapy (RT) <30 y of age

**Elements that decrease risk**
- Prior oophorectomy before age 45 y
- Prior risk-reducing therapy
- Exercise
- Breastfeeding

### Risk Assessment

- Prior thoracic RT <30 y of age
- History of LCIS
- Atypical hyperplasia (ductal and lobular)
- Life expectancy <10 y
- Life expectancy ≥10 y
- 5-y breast cancer risk ≥1.7% and Life expectancy ≥10 y
- 5-y breast cancer risk <1.7% or Life expectancy <10 y or Contraindication to endocrine risk-reducing therapies

### Risk Management

- Woman does not meet any of the familial risk criteria or tests negative for a genetic predisposition
- See NCCN Guidelines for Breast Cancer Screening and Diagnosis
- Woman desires risk-reducing therapy (See BRISK-5)
- Risk-reducing counseling
- See NCCN Guidelines for Breast Cancer Screening and Diagnosis

Note: All recommendations are category 2A unless otherwise indicated.
Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
See life expectancy calculator (www.eprognosis.com). For a reference point, the life expectancy of the average 78-year-old woman in the United States is 10.2 years. (See NCCN Guidelines for Older Adult Oncology).

See Components of Risk/Benefit Assessment and Counseling (BRISK-A).

The management for women with DCIS and invasive breast cancer is available in the NCCN Guidelines for Breast Cancer.

For example, there is an increased incidence of specific BRCA1/2 mutations in women of Ashkenazi Jewish decent.

See NCCN Guidelines for Breast Cancer Screening and Diagnosis for classic LCIS and NCCN Guidelines for Breast Cancer for pleomorphic LCIS.

Women with atypical hyperplasia have an 86% reduction in risk with therapy. Risk-reducing therapy should be strongly recommended for women with atypical hyperplasia and LCIS.

The data are not strong with respect to the degree of risk or the benefits of risk-reducing therapy in this population. The Gail Model does not apply to women with FEA.

The clinical utility and role of random periareolar fine-needle aspiration, nipple aspiration, or ductal lavage are still being evaluated and should only be used in the context of a clinical trial.

There are limitations to all of the models for risk assessment. The modified Gail Model (NCI Breast Cancer Risk Assessment Tool) is a computer-based version and may be obtained through the NCI website (http://www.cancer.gov/bcrisktool/Default.aspx). There are circumstances in which the Gail Model underestimates risk for development of breast cancer, for instance, BRCA1/2 carriers and those with a strong family history of breast cancer or family history of ovarian cancer in the maternal or paternal family lineage or non-white women or women with atypical hyperplasia, making them appear to be ineligible for risk-reducing therapy. The Claus, BRCAPRO, Tyrer-Cuzick, and BOADICEA models may be particularly helpful in determining risk for breast cancer in women with a strong family history of breast, ovarian, or other cancers. Tyrer-Cuzick overestimates risk in women with atypical hyperplasia and dense breasts. See Discussion.

The definition of risk as defined by the National Surgical Adjuvant Breast and Bowel Project Breast Cancer Prevention Trial (NSABP BCPT).
RISK-REDUCING THERAPY
NOT DESIRED

Woman does not desire risk-reducing therapy and Life expectancy ≥10 y

<table>
<thead>
<tr>
<th>RISK ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Pedigree suggestive of/or known genetic predisposition or Lifetime risk ≥20% based on models largely dependent on family history</td>
</tr>
<tr>
<td>History of LCIS or Atypical hyperplasia (ductal and lobular)</td>
</tr>
<tr>
<td>Prior thoracic RT &lt;30 y of age</td>
</tr>
<tr>
<td>5-y breast cancer risk ≥1.7%</td>
</tr>
</tbody>
</table>

SCREENING/FOLLOW-UP

See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Breast Cancer Screening and Diagnosis

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.

See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.

See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian and NCCN Guidelines for Breast Cancer Screening and Diagnosis.

See NCCN Guidelines for Breast Cancer Screening and Diagnosis.

See NCCN Guidelines for Breast Cancer Screening and Diagnosis for classic LCIS and NCCN Guidelines for Breast Cancer for pleomorphic LCIS.

Women with atypical hyperplasia have an 86% reduction in risk with therapy. Risk-reducing therapy should be strongly recommended for women with atypical hyperplasia and LCIS.

The definition of risk as defined by the NSABP BCPT.

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
**BRISK-5**

**Risk-Reducing Therapy Desired**

**Baseline Assessment**

Lifestyle modification

- Risk-reducing agent(s)  
  - Baseline gynecologic assessment (for women with intact uterus)  
  - Baseline bone density evaluation (for post-menopausal women only)

- Clinical trial  
  - Tamoxifen (category 1)

- Pre-menopausal

- Post-menopausal

**Risk-Reducing Intervention Follow-Up**

- Surveillance according to NCCN Guidelines for Breast Cancer Screening and Diagnosis for women at increased risk for breast cancer
- Routine age-appropriate gynecologic screening (for women with intact uterus on tamoxifen)
- Ophthalmology exam if cataracts or vision problems
- For management while on endocrine therapy, see BRISK-7
- Monitor bone density while on aromatase inhibitors

**Follow-Up**

- See BRISK-A

**Note:** All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
RISK-REDUCING INTERVENTION

Risk-reducing surgery

- Risk-reducing mastectomy desired\textsuperscript{aa}

and/or

- Risk-reducing bilateral salpingo-oophorectomy\textsuperscript{bb} desired

\textsuperscript{aa}Risk-reducing mastectomy should generally be considered only in women with a genetic mutation conferring a high risk for breast cancer (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian, Table on GENE-2), compelling family history, or possibly with prior thoracic RT at <30 years of age. While this approach has been previously considered for LCIS, the currently preferred approach is risk-reducing therapy. The value of risk-reducing mastectomy in women with deleterious mutations in other genes associated with a 2-fold or greater risk for breast cancer (based on large epidemiologic studies) in the absence of a compelling family history of breast cancer is unknown.


See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian

Note: All recommendations are category 2A unless otherwise indicated.

Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
## CLINICAL SCENARIOS

### MANAGEMENT WHILE ON RISK-REDUCING THERAPY

<table>
<thead>
<tr>
<th>Scenario</th>
<th>Management</th>
</tr>
</thead>
<tbody>
<tr>
<td>Asymptomatic</td>
<td>Continue risk-reducing agent</td>
</tr>
<tr>
<td>Arthralgias (exemestane, anastrozole)</td>
<td>Symptomatic treatment if persist, reevaluate role of risk-reducing agent</td>
</tr>
<tr>
<td>Hot flashes or other risk-reducing, agent-related symptoms (tamoxifen, raloxifene, exemestane, anastrozole)</td>
<td>Symptomatic treatment if persist, reevaluate role of risk-reducing agent</td>
</tr>
<tr>
<td>Osteopenia/osteoporosis</td>
<td>Monitor bone density while on aromatase inhibitors&lt;sup&gt;cc&lt;/sup&gt;</td>
</tr>
<tr>
<td>Abnormal vaginal bleeding (tamoxifen therapy)</td>
<td>Prompt evaluation for endometrial cancer if uterus intact</td>
</tr>
<tr>
<td>Deep vein thrombosis, pulmonary embolism, cerebrovascular accident, or prolonged immobilization (tamoxifen and raloxifene)</td>
<td>Discontinue tamoxifen or raloxifene, treat underlying condition</td>
</tr>
</tbody>
</table>

<sup>cc</sup>Weight-bearing exercise or use of a bisphosphonate (oral/IV) or denosumab is acceptable to maintain or to improve bone mineral density and reduce risk of fractures in women receiving aromatase inhibitors. Women treated with a bisphosphonate or denosumab should undergo a dental examination with preventive dentistry prior to the initiation of therapy, and should take supplemental calcium and vitamin D.

---

**Note:** All recommendations are category 2A unless otherwise indicated. Clinical Trials: NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
COMPONENTS OF RISK/BENEFIT ASSESSMENT AND COUNSELING

Options for risk reduction should be discussed in a shared decision-making environment. For breast cancer risk reduction, elements of this discussion include:

- If a woman is at high risk secondary to a strong family history or very early onset of breast or ovarian cancer, genetic counseling should be offered. See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian.

- Healthy lifestyle
  - Consider breast cancer risks associated with combined estrogen/progesterone therapy ≥3–5 year's duration of use.
  - Alcoholic drinks increase the risk for breast cancer; limit alcohol consumption.
  - Exercise
    - For premenopausal women, be vigorously physically active.
    - For postmenopausal women, be at least moderately physically active. Be active daily, taking part each week in at least 150 minutes of moderate-intensity, aerobic physical activity or at least 75 minutes of vigorous, aerobic physical activity (or a combination).
  - Weight control
    - For postmenopausal women, be a healthy weight and avoid weight gain.
  - Breastfeeding

- Risk-reducing agents - See the Discussion section.
  - Discussion of relative and absolute risk reduction with tamoxifen, raloxifene, or aromatase inhibitors.
  - Contraindications to tamoxifen or raloxifene: history of deep vein thrombosis, pulmonary embolus, thrombotic stroke, transient ischemic attack, or known inherited clotting trait.
  - Contraindications to tamoxifen, raloxifene, and aromatase inhibitors: current pregnancy or pregnancy potential without effective nonhormonal method of contraception.
  - Common and serious adverse effects of tamoxifen, raloxifene, or aromatase inhibitors with emphasis on age-dependent risks.

- Risk-reducing surgery
  - Risk-reducing mastectomy should generally be considered only in women with a genetic mutation conferring a high risk for breast cancer (See NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian, Tables on GENE-2, GENE-3, and GENE-4), compelling family history, or possibly with prior thoracic RT at <30 years of age. While this approach has been previously considered for LCIS, the currently preferred approach is risk-reducing therapy. The value of risk-reducing mastectomy in women with deleterious mutations in other genes associated with a two-fold or greater risk for breast cancer (based on large epidemiologic studies) in the absence of a compelling family history of breast cancer is unknown.

- Option of participation in clinical research for screening, risk assessment, or other risk-reducing intervention.

1 See American Cancer Society Guidelines.
2 Exemestane and anastrozole are not currently FDA approved for breast cancer risk reduction. There are currently no data comparing the benefits and risks of exemestane and anastrozole to those of tamoxifen or raloxifene.
### BREAST CANCER RISK-REDUCING AGENTS

<table>
<thead>
<tr>
<th>Tamoxifen&lt;sup&gt;1,2,3&lt;/sup&gt;</th>
<th>Raloxifene&lt;sup&gt;1,2&lt;/sup&gt;</th>
<th>Aromatase Inhibitors (exemestane and anastrozole)&lt;sup&gt;4&lt;/sup&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>Data regarding tamoxifen risk reduction are limited to pre- and postmenopausal women 35 years of age or older with a Gail Model 5-year breast cancer risk of ≥1.7% or a history of LCIS.</td>
<td>Data regarding raloxifene risk reduction are limited to postmenopausal women 35 years of age or older with a Gail Model 5-year breast cancer risk of ≥1.7% or a history of LCIS.</td>
<td>Data regarding exemestane are from a single large randomized study limited to postmenopausal women 35 years of age or older with a Gail Model 5-year breast cancer risk of ≥1.7% or a history of LCIS.</td>
</tr>
<tr>
<td>Tamoxifen: 20 mg per day for 5 years was shown to reduce risk of breast cancer by 49%. Among women with a history of atypical hyperplasia, this dose and duration of tamoxifen was associated with an 86% reduction in breast cancer risk.</td>
<td>Raloxifene: 60 mg per day was found to be equivalent to tamoxifen for breast cancer risk reduction in the initial comparison. While raloxifene in long-term follow-up appears to be less efficacious in risk reduction than tamoxifen, consideration of toxicity may still lead to the choice of raloxifene over tamoxifen in women with an intact uterus.</td>
<td>Data regarding anastrozole are from a single large randomized study limited to postmenopausal women 40 to 70 years of age with the following risk compared with the general population:</td>
</tr>
<tr>
<td>The efficacy of tamoxifen risk reduction in women who are carriers of BRCA1/2 mutations or who have had prior thoracic radiation is less well studied than in other risk groups. Limited retrospective data suggest there may be a benefit.</td>
<td>There are no data regarding the use of raloxifene in women who are carriers of BRCA1/2 mutations or who have had prior thoracic radiation.</td>
<td>Aged 40 to 44 years - 4 times higher</td>
</tr>
<tr>
<td>For healthy high-risk premenopausal women, data regarding the risk/benefit ratio for tamoxifen appear relatively favorable (category 1).</td>
<td>For high-risk postmenopausal women, data regarding the risk/benefit ratio for raloxifene are influenced by age or comorbid conditions (category 1). There are insufficient data on ethnicity and race.</td>
<td>Aged 45 to 60 years - ≥2 times higher</td>
</tr>
<tr>
<td>For high-risk postmenopausal women, data regarding the risk/benefit ratio for tamoxifen are influenced by age, presence of uterus, or comorbid conditions (category 1). There are insufficient data on ethnicity and race.</td>
<td>Use of raloxifene for breast cancer risk reduction in premenopausal women is inappropriate unless part of a clinical trial.</td>
<td>Aged 60 to 70 years - ≥1.5 times higher</td>
</tr>
</tbody>
</table>

1. There are limited data regarding >5 years of tamoxifen or raloxifene use in breast cancer prevention. Moreover, there may be safety concerns related to use of tamoxifen for greater than 5 years. Based on the recent update of the STAR trial data, continuing raloxifene beyond 5 years (there are no high-level experience or clinical trial data evaluating these agents for risk reduction beyond 5 years) may be an approach to maintain the risk-reducing activity of the agent.
3. Some selective serotonin reuptake inhibitors (SSRIs) decrease the formation of endoxifen, the active metabolite of tamoxifen. However, citalopram and venlafaxine appear to have minimal impact on tamoxifen metabolism. The clinical impact of these observations is not known.
4. Exemestane and anastrozole are not currently FDA approved for breast cancer risk reduction. There are currently no data comparing the benefits and risks of exemestane and anastrozole to those of tamoxifen or raloxifene.

**Note:** All recommendations are category 2A unless otherwise indicated.

**Clinical Trials:** NCCN believes that the best management of any patient with cancer is in a clinical trial. Participation in clinical trials is especially encouraged.
Discussion

This discussion is being updated to correspond with the newly updated algorithm. Last updated 04/23/18

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Table of Contents

Overview ........................................................................................................MS-2

Literature Search Criteria and Guidelines Update Methodology........MS-2

Elements of Risk and Risk Assessment ............................................MS-3

Familial/Genetic Risk Factors ..........................................................MS-3

Other Elements of Risk .......................................................................MS-4

Cancer Risk Assessment .....................................................................MS-5

Risk-Reduction Interventions .............................................................MS-6

Lifestyle Modifications ..........................................................................MS-6

Risk-Reduction Surgery.................................................................MS-7

Risk-Reduction Agents .................................................................MS-7

Tamoxifen for Risk Reduction .......................................................MS-7

Raloxifene for Risk Reduction .......................................................MS-9

Aromatase Inhibitors for Risk Reduction .........................................MS-12

NCCN Breast Cancer Risk Reduction Panel Recommendations for Risk-Reduction Agents ........................................MS-13

Monitoring Patients on Risk Reduction Agents ............................MS-15

Endometrial Cancer ........................................................................MS-15

Retinopathy and Cataract Formation ...........................................MS-16

Bone Mineral Density .........................................................................MS-16

Thromboembolic Disease and Strokes ..........................................MS-17

Managing Side Effects of Risk-Reduction Agents ......................MS-17

Components of Risk-Reduction Counseling ..................................MS-19

Counseling Prior to Therapy with Risk-Reduction Agents ..........MS-20

Counseling Prior to Risk Reduction Surgery ................................MS-22

Counseling Regarding Lifestyle Modifications ............................MS-23

Summary .............................................................................................MS-26

References ...........................................................................................MS-29
Overview
Breast cancer is the most commonly diagnosed cancer in American women, with an estimated 268,670 cases of invasive breast cancer and an estimated death toll of 41,400 women in 2018. This highlights the need for effective breast cancer screening and risk-reduction strategies.

For a woman who does not have a personal history of breast cancer, the risk factors for the development of breast cancer can be grouped into categories, including familial/genetic factors; factors related to demographics; reproductive history; lifestyle factors; and other factors such as number of breast biopsies, especially those finding flat epithelial atypia (FEA), atypical hyperplasia (AH), or lobular carcinoma in situ (LCIS), breast density, or thoracic irradiation before 30 years of age (eg, to treat Hodgkin’s disease).

Estimating breast cancer risk for an individual is difficult, and most breast cancers are not attributable to risk factors other than female gender and increasing age. In the United States, 266,120 women are diagnosed with invasive breast cancer annually, compared with approximately 2550 cases that occur annually in men.

The development of effective strategies for the reduction of breast cancer incidence has also been difficult, because few of the existing risk factors are modifiable and some of the potentially modifiable risk factors have social implications extending beyond concerns for breast cancer (eg, age at first live birth). Nevertheless, effective breast cancer risk-reduction strategies such as use of risk-reduction agents and risk-reduction surgery have been identified. Women and their physicians who are considering interventions to reduce risk for breast cancer must balance the demonstrated benefits with the potential morbidities of the interventions. Surgical risk-reduction strategies (eg, risk-reduction bilateral mastectomy) may have psychosocial and/or physical consequences for the woman, and risk-reduction agents, used for non-surgical risk reduction, are associated with certain adverse effects. To assist women who are at increased risk of developing breast cancer and their physicians in the application of individualized strategies to reduce breast cancer risk, NCCN has developed these guidelines for breast cancer risk reduction.

Literature Search Criteria and Guidelines Update Methodology
Before the update of this version of the NCCN Guidelines for Breast Cancer Risk Reduction, an electronic search of the PubMed database was performed to obtain key literature using the following search terms: Breast Cancer Risk Assessment; Breast Cancer Risk Reduction; and Breast Cancer Risk Reduction Therapies. The search results were narrowed by selecting studies in humans published in English. An updated search was carried out before the publication of this document. The PubMed database was chosen as it remains the most widely used resource for medical literature and indexes peer-reviewed biomedical literature.

Search results were confined to the following article types: Clinical Trial, Phase II; Clinical Trial, Phase III; Clinical Trial, Phase IV; Guideline; Randomized Controlled Trial; Meta-Analysis; Systematic Reviews; and Validation Studies.

The potential relevance of the PubMed search citations over the past year was examined. The data from key PubMed articles as well as articles from additional sources deemed as relevant to these Guidelines and/or discussed by the panel have been included in this version of the Discussion section (eg, e-publications ahead of print, meeting abstracts).
Any recommendations for which high-level evidence is lacking are based on the panel's review of lower-level evidence and expert opinion.

The complete details of the development and update of the NCCN Guidelines are available on the NCCN webpage.

Elements of Risk and Risk Assessment

Estimation of breast cancer risk for a woman who does not have a personal history of invasive breast cancer or ductal carcinoma in situ (DCIS) begins with an initial assessment of familial/genetic factors associated with increased breast cancer risk for the purpose of determining whether more extensive genetic risk assessment and counseling should be undertaken.

Familial/Genetic Risk Factors

The first step in this primary assessment is a broad and flexible evaluation of the personal and family history of the individual, primarily with respect to breast and/or ovarian cancer/fallopian tube or primary peritoneal cancer.6,7

Genetic predispositions conferring a high risk for breast cancer include hereditary breast and ovarian cancer (BRCA1/2).8,9 Li-Fraumeni syndrome (TP53),10 Peutz-Jeghers syndrome (STK11),11 Cowden syndrome (PTEN),12,13 and hereditary diffuse gastric cancer (CDH1).14

If the individual has a known genetic predisposition for breast cancer such as mutations in BRCA1/2, TP53, PTEN, or other genes associated with breast cancer risk, that individual must be counseled about risk reduction options.

If the familial/genetic factors are not known, a thorough evaluation must be performed. The magnitude of the risk increases with the number of affected relatives in the family, the closeness of the relationship, and the age at which the affected relative was diagnosed.15-17 The younger the age at diagnosis of the first- or second-degree relative, the more likely it is that a genetic component is present. The maternal and paternal sides of the family should be considered independently for familial patterns of cancer (see NCCN Guidelines for Genetic/Familial Risk Assessment: Breast and Ovarian).

Hereditary cancers are often characterized by gene mutations associated with a high probability of cancer development (ie, a high penetrance genotype), vertical transmission through either mother or father, and an association with other types of tumors.18,19 They often have an early age of onset and exhibit an autosomal-dominant inheritance pattern (ie, they occur when the individual has a germline mutation in only one copy of a gene).

Familial cancers share some but not all features of hereditary cancers. For example, although familial breast cancers occur in a given family more frequently than in the general population, they generally do not exhibit the inheritance patterns or age of onset consistent with hereditary cancers. Familial cancers may be associated with chance clustering of sporadic cancer cases within families, genetic variation in lower penetrance genes, a shared environment, or combinations of these factors.20-23

If an individual or a close family member of that individual meets one or more of the criteria listed in the NCCN Guidelines for Breast Cancer Risk Reduction under “Familial Risk Assessment” (and also NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian), that individual may be at increased risk for familial/hereditary breast cancer, and referral for formal genetic assessment/counseling is recommended.

A cancer genetics professional should be involved in determining whether the individual has a lifetime risk for breast cancer greater than 20% based...
on models dependent on family history (eg, Claus, Tyrer-Cuzick, others). The Claus tables may be useful in providing breast cancer risk estimates for white women with no known cancer-associated gene mutation but who have one or two first- or second-degree female relatives with breast cancer and ovarian cancer.

BRCAPRO and Breast and Ovarian Analysis of Disease Incidence and Carrier Estimation Algorithm (BOADICEA) are more commonly used to estimate the risk of a BRCA mutation. Strong genetic association between breast and ovarian cancer has been demonstrated in some families by linkage analyses. Based on a risk assessment using one or more of these models, women with a BRCA1/2, TP53, or PTEN gene mutation, or a pedigree strongly suggestive of genetic predisposition to breast cancer, may be identified. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian describe management strategies for women with a known or suspected BRCA1/2, TP53, or PTEN mutation or a pedigree strongly suggestive of genetic predisposition to breast cancer.

Other Elements of Risk

For women not considered to be at risk for familial/hereditary breast cancer, an evaluation of other elements of risk that contribute to increased breast cancer risk is recommended. These include demographic factors such as female gender, age, and ethnicity/race. There is an increased incidence of BRCA1/2 mutation reported in women of Ashkenazi Jewish decent.

Reproductive history is another factor to consider. Risk factors linked to reproductive history include nulliparity, prolonged interval between menarche and age at first live birth (eg, early menarche or late age at first live birth), onset of menarche at a younger age, or onset of menopause at older age. Body mass index (BMI) is an independent risk factor for breast cancer, especially in Caucasian women. Several studies have established the association between high BMI and adult weight gain and increased risk for breast cancer in postmenopausal women. This increase in risk has been attributed to increase in circulating endogenous estrogen levels from fat tissue. In addition, the association between BMI and risk for postmenopausal breast cancer is stronger for hormone-positive tumors. A meta-analysis of more than 1000 epidemiologic studies looked at cancer risk with excess body fat. Women with higher BMI experienced an increased risk of postmenopausal breast cancer (relative risk [RR] 1.1 per 5 BMI units, 95% CI 1.1–1.2). Lifestyle factors such as current or prior hormone therapy (HT), alcohol consumption, and, to a lesser extent, smoking also contribute to the risk of developing breast cancer.

The risk for breast cancer associated with FEA is similar to that of benign proliferative disease without atypia. The data are not as strong with respect to the degree of risk or the benefits of risk-reduction therapy in this population. Proliferative lesions with atypia include atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), and LCIS. These lesions are associated with an increased risk of developing breast cancer. Women with LCIS are at substantially increased risk for breast cancer. In a population-based study of 19,462 women diagnosed with LCIS from the SEER database between 1983 and 2014 in whom the cumulative incidences of subsequent breast malignancy were 11.3% (95% CI, 10.7–11.9%) and 19.8% (95% CI, 18.8–20.9%) at 10 and 20 years, respectively. At a median follow-up of 8.1 years (range 0–30.9 years), primary breast cancer was diagnosed in 9.4% of the cohort. Other factors to consider are number of breast biopsies, done with the intent to diagnose cancer.
Individuals receiving early thoracic irradiation encompassing the chest/breast area before age 30 (eg, to treat Hodgkin’s disease) is a significant risk factor for the development of breast cancer. In the Late Effects Study Group trial, the overall risk for breast cancer associated with thoracic irradiation at a young age was found to be 56.7-fold (55.5-fold for female patients) greater than the risk for breast cancer in the general population. In that study, the RR according to follow-up interval was: 0 at 5 to 9 years; 71.3 at 10 to 14 years; 90.8 at 15 to 19 years; 50.9 at 20 to 24 years; 41.2 at 25 to 29 years; and 24.5 at >29 years. Results from a case-control study of women treated at a young age (≤30 years) for Hodgkin lymphoma with thoracic radiation indicated that the estimated, cumulative, absolute risk for breast cancer at 55 years of age was 29.0% (95% CI, 20.2%–40.1%) for a woman treated at 25 years of age with 40 Gy of radiation and no alkylating agents. Women with a history of treatment with thoracic radiation for Hodgkin’s disease are at high risk for breast cancer on the basis of radiation exposure alone.

Change in breast density has been suggested as a risk factor for breast cancer. Dense breast tissue as measured by mammography is increasingly recognized as an important risk factor for breast cancer. For example, a report of a large case-cohort study of women 35 years and older with no history of breast cancer who underwent mammographic screening, first at baseline and then at an average of 6 years later, suggested that longitudinal changes in breast density are associated with changes in breast cancer risk.

There are many elements that may reduce the risk of cancer. Breast feeding has been shown to have a protective effect in many studies. An analysis of 47 epidemiologic studies (50,302 women with invasive breast cancer and 96,973 controls) estimated that for every 12 months of breastfeeding, RR for breast cancer decreases by 4.3%.

Exercise has also been shown to reduce the risk of breast cancer, especially in post-menopausal women. A most recent review of epidemiologic studies estimated that risk of breast cancer was reduced among women who were most physically active compared with those who were least active (RR, 0.88; 95% CI, 0.85–0.90).

Oophorectomy before age 45 years and risk-reduction therapy have a protective effect. A large prospective study examined associations of hysterectomy with bilateral salpingo-oophorectomy (BSO) and simple hysterectomy in 66,802 postmenopausal women from the Cancer Prevention Study-II Nutrition Cohort. The results showed that hysterectomy with BSO performed at any age (n = 1892), compared with no hysterectomy (n = 5586), is associated with a 10% reduction in all cancers (RR, 0.90; 95% CI, 0.85–0.96).

Cancer Risk Assessment

The modified Gail model is a computer-based, multivariate, logistic regression model that uses age, race, age at menarche, age at first live birth or nulliparity, number of first-degree relatives with breast cancer, number of previous breast biopsies, and histology of the breast biopsies to produce actuarial estimates of future breast cancer risk. The criteria used to determine risk by the modified Gail model are described in Table 1.

The Gail model was initially modified by the National Surgical Adjuvant Breast and Bowel Project (NSABP) investigators. It has subsequently been updated using combined data from the Women’s Contraceptive and Reproductive Experiences (CARE) study and the SEER database, as well as causes of death from the National Center for Health Statistics, to provide a more accurate determination of risk for African American women. The model was also updated using data from the Asian
American Breast Cancer Study (AABCS) and the SEER database to provide a more accurate risk assessment for Asian and Pacific Islander women in the United States.\textsuperscript{97} Application of the Gail model to recent immigrants from Japan or China may overestimate the risk for breast cancer.\textsuperscript{97} The most recent version of the Gail model is available on the National Cancer Institute website (http://www.cancer.gov/bcrisktool/Default.aspx).

Women ≥35 years of age should have their risk for breast cancer estimated according to the modified Gail model.\textsuperscript{92,93,98} The Gail model is not an appropriate breast cancer risk assessment tool for women with a BRCA1/2, TP53, or PTEN mutation; a strong family history of breast cancer; women who received thoracic radiation to treat Hodgkin’s disease (eg, mantle radiation); or those with LCIS.\textsuperscript{99} While the Gail model can overestimate the risk for some women, in some others, notably women with AH, it can underestimate their risk making them appear to be ineligible for risk-reduction therapy. The Gail model does not apply to women with FEA.

The risk threshold required to consider the use of risk-reduction strategies must depend on an evaluation of the efficacy, morbidity, and expense of the proposed intervention. As a reasonable discriminating threshold, the NCCN Breast Cancer Risk Reduction Panel has adopted the 1.7% or greater 5-year actuarial breast cancer risk as defined by the modified Gail model, which was used to identify women eligible for the NSABP Breast Cancer Prevention Trial (BCPT)\textsuperscript{100,101} and the Study of Tamoxifen and Raloxifene (STAR) trial.\textsuperscript{102,103}

The Tyrer-Cuzick model, in addition to considering a woman’s risk of a BRCA mutation, also estimates her risk of developing breast cancer using not only family history but also epidemiologic variables including a personal history of AH or LCIS. Women with AH or a history of LCIS are also at substantially increased risk for invasive breast cancer in both the affected and contralateral breast.\textsuperscript{65-67,104,105}

In an analysis of the Mayo Clinic cohort of more than 300 women with AH, the Gail model underestimated breast cancer risk for women with AH,\textsuperscript{99} whereas the Tyrer-Cuzick model overestimated this risk.\textsuperscript{106} Breast density is not included in any of the commonly used risk assessment models/tools.\textsuperscript{27}

Women with a life expectancy ≥10 years and no diagnosis/history of breast cancer who are considered to be at increased risk for breast cancer based on any of the above-mentioned assessments, should receive counseling and should undergo breast screening as detailed in the NCCN Guidelines for Breast Cancer Screening and Diagnosis. The counseling should be tailored to the individual, to decrease breast cancer risk (eg, risk-reduction surgery in BRCA1/2 mutation carriers; therapy with risk-reduction agents in those without a contraindication to these agents) (see section below on Components of Risk-Reduction Counseling).

If life expectancy is <10 years, there is probably minimal if any benefit to risk-reduction therapy or screening (see NCCN Guidelines for Breast Cancer Screening and Diagnosis and NCCN Guidelines for Breast Cancer).

Women with a diagnosis of DCIS should be managed according to recommendations outlined in the NCCN Guidelines for Breast Cancer.

**Risk-Reduction Interventions**

**Lifestyle Modifications**

Evidence from immigration studies indicates that in addition to family history and genetics, environmental factors play a significant role. As discussed under Other Elements of Risk, life style factors such as lack of
exercise and alcohol consumption are linked with risk of developing breast cancer and are some of the modifiable components.

Patients should be encouraged to maintain a healthy lifestyle and to remain up-to-date with recommendations for screening and surveillance (see Counseling Regarding Lifestyle Modifications).

Risk-Reduction Surgery
Risk-reducing mastectomy (RRM) should generally be considered only in women with a genetic mutation conferring a high-risk for breast cancer.

Data have supported a protective effect of bilateral oophorectomy, although now there are conflicting reports that challenge that observation. The NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian discuss the recommendations for risk-reduction surgery (mastectomy and bilateral oophorectomy) in detail.

Risk-Reduction Agents
Risk-reduction agents (ie, tamoxifen, raloxifene, anastrozole, exemestane) are recommended for women ≥35 years of age only, as the utility of these agents in women younger than 35 years is unknown. Tamoxifen is the only agent indicated for premenopausal women, whereas all 4 agents may be used in postmenopausal women.

**Tamoxifen for Risk Reduction**
The benefits of tamoxifen, a selective estrogen receptor (ER) modulator (SERM), in the treatment of breast cancer in the adjuvant and metastatic settings are well documented. Retrospective analysis of randomized, controlled, clinical trials comparing tamoxifen to no tamoxifen in the adjuvant treatment of women with breast cancer has shown a reduction in the incidence of contralateral second primary breast cancer. The meta analyses by Early Breast Cancer Trialists’ Collaborative Group confirmed that the risk for contralateral primary breast cancer is substantially reduced (ie, a statistically significant annual recurrence rate ratio = 0.59) by 5 years of tamoxifen therapy in women with first breast cancers that are ER-positive or have an unknown ER status.

**NSABP Breast Cancer Prevention Trial**
The effectiveness of tamoxifen in the setting of breast cancer treatment gave rise to the NSABP BCPT study, also known as the P-1 study. It was a randomized clinical trial of healthy women aged 60 years or older, aged 35 to 59 years with a 1.7% or greater cumulative 5-year risk for developing breast cancer, or with a history of LCIS. Both premenopausal and postmenopausal women were enrolled in the trial and randomized in a double-blinded fashion to treatment with tamoxifen, 20 mg daily for 5 years, or placebo. Invasive breast cancer incidence was the primary study endpoint; high-priority secondary endpoints included the occurrence of thromboembolic disease, cardiovascular disease, bone fracture, endometrial cancer, noninvasive breast cancer, and breast cancer mortality. The trial was unblinded and initial findings were reported in 1998. A subsequent report on this trial has been published, which takes into account 7 years of follow-up data subsequent to the point where the study was unblinded. However, nearly one-third of the placebo participants began taking a SERM when the study was unblinded, which decreased the proportion of women in the placebo group relative to the tamoxifen group, potentially confounding the long-term results. The results of the P-1 study showed that treatment with tamoxifen decreased the short-term risk for breast cancer by 49% in healthy women aged 35 years or older who had an increased risk for the disease. Risk-reduction benefits were demonstrated across all age groups, in pre-menopausal and post-menopausal women. The difference in average annual rates for invasive breast cancer was 3.30 cases per 1000 women (ie, 6.76 cases per 1000 women in the placebo group and 3.43 cases per 1000 women in the group...
taking tamoxifen). The absolute risk reduction was 21.4 cases per 1000 women over 5 years.\(^{100}\) In terms of numbers needed to treat, this corresponds to treatment of 47 women with tamoxifen to prevent 1 case of invasive breast cancer. Updated results indicate that breast cancer risk was reduced by 43% in this population after 7 years of follow-up.\(^{101}\) The reduction in invasive breast cancer risk in participants with AH was particularly striking (RR, 0.14; 95% CI, 0.03–0.47) in the initial study analysis, and an RR of 0.25 (95% CI, 0.10–0.52) was found after 7 years of follow-up. An additional benefit of tamoxifen was a decrease in bone fractures (RR, 0.81; 95% CI, 0.63–1.05). However, as was anticipated from the experience in studies of women taking tamoxifen following a breast cancer diagnosis, major toxicities included hot flashes, invasive endometrial cancer in postmenopausal women, and cataracts. A significant increase in the incidence of pulmonary embolism was also observed in women ≥50 years of age taking tamoxifen. The average annual rates of pulmonary embolism per 1000 women were 1.00 versus 0.31 (RR, 3.19; 95% CI, 1.12–11.15).\(^{100}\)

No differences were observed in overall rates of mortality by treatment group with a follow-up period of up to 7 years. The initial study analysis revealed that average annual mortality from all causes in the tamoxifen group was 2.17 per 1000 women compared with 2.71 per 1000 women treated with placebo, for an RR of 0.81 (95% CI, 0.56–1.16).\(^{100}\) Annual mortality after 7 years of follow-up was 2.80 per 1000 women compared with 3.08 per 1000 women in the tamoxifen and placebo groups, respectively, for an RR of 1.10 (95% CI, 0.85–1.43).\(^{101}\)

An evaluation of the subset of patients with a \(BRCA1/2\) mutation in the P-1 study revealed that breast cancer risk was reduced by 62% in study patients with a \(BRCA2\) mutation receiving tamoxifen relative to placebo (RR, 0.38; 95% CI, 0.06–1.56). However, tamoxifen use was not associated with a reduction in breast cancer risk in patients with a \(BRCA1\) mutation.\(^{113}\) These findings may be related to the greater likelihood of development of ER-positive tumors in \(BRCA2\) mutation carriers relative to \(BRCA1\) mutation carriers. However, this analysis was limited by the very small number of patients with a \(BRCA1/2\) mutation. Currently, there are no prospective studies evaluating the risk-reductive effect of tamoxifen in \(BRCA\) mutation carriers.

Based on the P-1 study results, in October 1998 the FDA approved tamoxifen for breast cancer risk reduction for women at increased risk for breast cancer.

### European Studies of Tamoxifen

Three European studies comparing tamoxifen with placebo for breast cancer risk reduction have been reported. The Royal Marsden Hospital study was a pilot trial of tamoxifen versus placebo in women ages 30 to 70 years who were at increased breast cancer risk based largely on their family history.\(^{114,115}\) Women in the trial were allowed to continue or to initiate postmenopausal HT. With 2471 participants available for interim analysis, no difference in the frequency of breast cancer was observed between the 2 study groups. Moreover, the toxicity experienced by the 2 groups did not show statistically significant differences.\(^{115}\) An analysis of updated findings from the Royal Marsden Hospital study demonstrated a nonsignificant breast cancer risk-reduction benefit with tamoxifen use (ie, 62 cases of breast cancer in 1238 women receiving tamoxifen vs. 75 cases of breast cancer in 1233 women in the placebo arm).\(^{114}\)

An analysis of blinded results from the Royal Marsden Hospital study at 20-year follow-up showed no difference in breast cancer incidence between the groups randomly assigned to tamoxifen or placebo (HR, 0.78; 95% CI, 0.58–1.04; \(P = .10\)).\(^{116}\) However, the incidence of ER-positive breast cancer was significantly lower in the tamoxifen arm vs. placebo arm.
of the trial (HR, 0.61; 95% CI, 0.43–0.86; \( P = .005 \)). Importantly, the difference between the 2 arms became significant only in the posttreatment period (ie, after 8 years of treatment).

The Italian Tamoxifen Prevention Study randomized 5408 women ages 35 to 70 years without breast cancer, who had undergone a previous hysterectomy, to receive tamoxifen or placebo for 5 years.\(^{117}\) Women in the trial were allowed to receive HT. No significant difference in breast cancer occurrence in the overall study population was identified at median follow-up periods of 46, 81.2, and 109.2 months.\(^{117-119}\) Thromboembolic events, predominantly superficial thrombophlebitis, were increased in women treated with tamoxifen. A subset of women in the Italian Tamoxifen Prevention Study who had used HT and were classified as at increased breast cancer risk based on reproductive and hormonal characteristics were found to have a significantly reduced risk for breast cancer with tamoxifen therapy.\(^{119,120}\) However, only approximately 13% of the patients in the trial were at high risk for breast cancer.

It is unclear why no overall breast cancer risk reduction was observed in the Italian Tamoxifen Prevention Study. Possible reasons include concurrent use of HT, and different study populations (ie, populations at lower risk for breast cancer).\(^{121}\)

The first International Breast Cancer Intervention Study (IBIS-I) randomized 7152 women aged 35 to 70 years at increased risk for breast cancer to receive either tamoxifen or placebo for 5 years.\(^{122}\) Tamoxifen provided a breast cancer (invasive breast cancer or DCIS) risk reduction of 32% (95% CI, 8–50; \( P = .013 \)). Thromboembolic events increased with tamoxifen (OR, 2.5; 95% CI, 1.5–4.4; \( P = .001 \)), and endometrial cancer showed a nonsignificant increase (\( P = .20 \)). An excess of deaths from all causes was seen in the tamoxifen-treated women (\( P = .028 \)).

After a median follow-up of 8 years a significant reduction for all types of invasive breast cancer was reported (RR, 0.73 [95% CI, 0.58–0.91; \( P = .004 \)]) with tamoxifen.\(^{123}\) Although no difference in the risk for ER-negative–invasive tumors was observed between the 2 groups, those in the tamoxifen arm were found to have a 34% lower risk for ER-positive invasive breast cancer.\(^{123}\) Slightly higher risk reduction with tamoxifen was observed for premenopausal patients. Importantly, the increased risk for venous thromboembolism (VTE) observed with tamoxifen during the treatment period was no longer significant in the posttreatment period. Gynecologic and vasomotor side effects associated with active tamoxifen treatment were not observed during the posttreatment follow-up.

The updated analysis after a median follow-up of 16 years confirmed that the preventive effect of tamoxifen continues with a significant reduction in the first 10 years (HR, 0.72 [95% CI, 0.59–0.88; \( P = .001 \))), and a slightly greater reduction in subsequent years (HR, 0.69, 0.53–0.91; \( P = .009 \)).\(^{124}\) A similar pattern was observed after the long-term follow-up for reduction in occurrence of invasive ER-positive breast cancer; a significant reduction for tamoxifen was also recorded for DCIS, but only in the first 10 years of follow-up. Interestingly, more ER-negative breast cancers were reported in the tamoxifen group after 10 years of follow-up than in the placebo group (HR, 2.45 [0.77–7.82]; \( P = .13 \)).\(^{124}\)

The use of tamoxifen as a breast cancer risk-reduction agent has been evaluated in the STAR trial\(^{102,103}\) (see The STAR Trial below).

**Raloxifene for Risk Reduction**

Raloxifene is a second-generation SERM that is chemically different from tamoxifen and appears to have similar anti-estrogenic effects with considerably less endometrial stimulation. The efficacy of raloxifene as a breast cancer risk-reduction agent has been evaluated in several clinical studies. In 2007, the FDA expanded the indications for raloxifene to
include reduction in risk for invasive breast cancer in postmenopausal women with osteoporosis, and reduction in risk for invasive breast cancer in postmenopausal women at high risk for invasive breast cancer.

**The MORE Trial**
The Multiple Outcomes of Raloxifene Evaluation (MORE) trial was designed to determine whether 3 years of raloxifene treatment reduced the risk of fracture in postmenopausal women with osteoporosis. A total of 7705 postmenopausal women 31 to 80 years of age were randomized to receive placebo, 60 mg/d of raloxifene, or 120 mg/d of raloxifene for 3 years. At study entry, participants were required to have osteoporosis (defined as a bone density at least 2.5 standard deviations below the mean for young women) or a history of osteoporotic fracture. The study showed a reduction in the vertebral fracture risk and an increase in bone mineral density (BMD) in the femoral neck and spine for the women treated with raloxifene, compared with those who received placebo.

After a median follow-up of 40 months in the MORE trial, breast cancer was reported in 40 patients: 27 cases in 2576 women receiving placebo and 13 cases in 5129 women receiving raloxifene. The RR of developing invasive breast cancer on raloxifene, compared with placebo, was 0.24 (95% CI, 0.13–0.44). Raloxifene markedly decreased the risk for ER-positive cancers (RR, 0.10; 95% CI, 0.04–0.24) but did not appear to influence the risk of developing an ER-negative cancer (RR, 0.88; 95% CI, 0.26–3.0). Although breast cancer incidence was a secondary endpoint in the MORE trial, it is important to note that breast cancer risk was not a prospectively determined characteristic for the women enrolled and stratified into treatment arms in this study. Furthermore, the patients enrolled in the MORE trial were, on average, at lower risk for breast cancer and older than the patients enrolled in the P-1 study.

Side effects associated with the raloxifene use included hot flashes, influenza-like syndromes, endometrial cavity fluid, peripheral edema, and leg cramps. In addition, there was an increased incidence of deep venous thromboses (DVT) (0.7% for women receiving 60 mg/d raloxifene vs. 0.2% for placebo) and pulmonary emboli (0.3% for women receiving 120 mg/d raloxifene vs. 0.1% for placebo) associated with raloxifene treatment. However, there was no increase in the risk for endometrial cancer associated with raloxifene.

**The CORE Trial**
The early findings related to breast cancer risk in the MORE trial led to the continuation of this trial under the name Continuing Outcomes Relevant to Evista (CORE) trial. Because breast cancer incidence was a secondary endpoint in the MORE trial, the CORE trial was designed to assess the effect of 4 additional years of raloxifene on the incidence of invasive breast cancer in postmenopausal women with osteoporosis. A secondary endpoint was the incidence of invasive ER-positive breast cancer. Data from the CORE trial were reported in 2004.

During the CORE trial, the 4-year incidence of invasive breast cancer was reduced by 59% (HR, 0.41; 95% CI, 0.24–0.71) in the raloxifene group compared with the placebo group. Raloxifene, compared to placebo, reduced the incidence of invasive ER-positive breast cancer by 66% (HR, 0.34; 95% CI, 0.18–0.66) but had no effect on invasive ER-negative breast cancers. Over the 8 years of both trials (MORE + CORE), the incidence of invasive breast cancer was reduced by 66% (HR, 0.34; 95% CI, 0.22–0.50) in the raloxifene group compared with the placebo group. Compared to placebo, 8 years of raloxifene reduced the incidence of invasive ER-positive breast cancer by 76% (HR, 0.24; 95% CI, 0.15–0.40). Interestingly, the incidence of noninvasive breast cancer was not
significantly different for patients in the raloxifene and placebo arms (HR, 1.78; 95% CI, 0.37–8.61).\textsuperscript{127}

The adverse events in the CORE trial were similar to those seen in the MORE trial. There was a nonsignificant increase in the risk for thromboembolism (RR, 2.17; 95% CI, 0.83–5.70) in the raloxifene group of the CORE trial compared to the placebo group. There was no statistically significant difference in endometrial events (bleeding, hyperplasia, and cancer) between the raloxifene and placebo groups during the 4 years of the CORE trial or the 8 years of the MORE and CORE trials. During the 8 years of the MORE and CORE trials, raloxifene increased the risk for hot flashes and leg cramps compared with placebo; these risks were observed during the MORE trial but not during the additional 4 years of therapy in the CORE trial. While it is possible that hot flashes and leg cramps are early events that do not persist with continued therapy, it is also possible that an increased risk for these adverse events was not observed in the CORE trial as a result of selection bias (ie, women who experienced these symptoms in the MORE trial may have chosen not to continue in the CORE trial).

The results from the CORE trial are not entirely straightforward because of the complex design of the trial. Of the 7705 patients randomized in the MORE trial, only 4011 chose to continue, blinded to therapy, in the CORE trial; this drop-off likely introduces bias in favor of the treatment group. In the CORE trial, the researchers did not randomize the patients again (1286 in the placebo arm, 2725 in the raloxifene arm), maintaining the double blinding of the original trial.

The RUTH Trial
In the Raloxifene Use for The Heart (RUTH) trial, postmenopausal women with an increased risk for coronary heart disease were randomly assigned to raloxifene or placebo arms.\textsuperscript{128,129} Invasive breast cancer incidence was another primary endpoint of the trial, although only approximately 40% of the study participants had an increased risk for breast cancer according to the Gail model. Median exposure to study drug was 5.1 years and median duration of follow-up was 5.6 years.\textsuperscript{129} Raloxifene did not reduce risk of cardiovascular events, but there was a 44% decrease in the incidence of invasive breast cancer in the raloxifene arm (HR, 0.56; 95% CI, 0.38–0.83), with a 55% lower incidence of ER-positive breast cancer (HR, 0.45; 95% CI, 0.28–0.72). No reduction in the risk for noninvasive breast cancer was found for patients receiving raloxifene, in agreement with the initial results of the STAR trial, although only 7% of breast cancers in the RUTH trial were noninvasive.

The STAR Trial
Despite issues of trial design, the results from the CORE trial and the previous MORE study provided support for concluding that raloxifene may be an effective breast cancer risk-reduction agent. However, neither of these studies was designed to directly evaluate the efficacy of raloxifene versus tamoxifen in this regard. This issue was addressed in the NSABP STAR trial (P-2), which was initiated in 1999; initial results became available in 2006.\textsuperscript{102}

In the STAR trial, 19,747 postmenopausal women 35 years or older at increased risk for invasive breast cancer as determined by the modified Gail model or with a personal history of LCIS were enrolled into one of two treatment arms (no placebo arm). The primary study endpoint was invasive breast cancer; secondary endpoints included quality of life, and incidences of noninvasive breast cancer, DVT, pulmonary embolism, endometrial cancer, stroke, cataracts, and death. At an average follow-up of approximately 4 years, no statistically significant differences between patients receiving 20 mg/d of tamoxifen or 60 mg/d of raloxifene were observed with respect to invasive breast cancer risk reduction (RR, 1.02;
Because there was no placebo arm, it was not possible to determine a raloxifene-versus-placebo RR for invasive breast cancer; however, tamoxifen was shown in the P-1 study to reduce breast cancer risk by nearly 50%. In addition, raloxifene was shown to be as effective as tamoxifen in reducing the risk for invasive cancer in the subset of patients with a history of LCIS or AH. However, raloxifene was not as effective as tamoxifen in reducing the risk for noninvasive breast cancer, although the observed difference was not statistically significant (RR, 1.40; 95% CI, 0.98–2.00).

At a median follow-up of nearly 8 years (81 months) involving 19,490 women, raloxifene was shown to be about 24% less effective than tamoxifen in reducing the risk for invasive breast cancer (RR, 1.24; 95% CI, 1.05–1.47), suggesting that tamoxifen has greater long-term benefit with respect to lowering invasive breast cancer risk. Raloxifene remained as effective as tamoxifen in reducing the risk for invasive cancer in women with LCIS (RR, 1.13; 95% CI, 0.76–1.69), but was less effective than tamoxifen for those with a history of AH (RR, 1.48; 95% CI, 1.06–2.09). Interestingly, at long-term follow-up, the risk for noninvasive cancer in the raloxifene arm grew closer to that observed for the group receiving tamoxifen (RR, 1.22; 95% CI, 0.95–1.50). No significant differences in mortality were observed between the 2 groups. In the initial analysis of the STAR trial data, invasive endometrial cancer occurred less frequently in the group receiving raloxifene compared with the tamoxifen group, although the difference did not reach statistical significance. It is important to note, however, that the incidence of endometrial hyperplasia and hysterectomy were significantly lower in the raloxifene group compared to the tamoxifen group. However, at long-term follow-up, the risk for endometrial cancer was significantly lower in the raloxifene arm (RR, 0.55; 95% CI, 0.36–0.83).

The lower incidences of thromboembolic events (RR, 0.75; 95% CI, 0.60–0.93) and cataract development (RR, 0.80; 95% CI, 0.72–0.89) observed in the raloxifene group compared to the tamoxifen group when the STAR trial results were initially analyzed were maintained at long-term follow-up. The incidences of stroke, ischemic heart disease, and bone fracture were similar in the two groups. In the initial report, overall quality of life was reported to be similar for patients in both groups, although patients receiving tamoxifen reported better sexual function.

Aromatase Inhibitors for Risk Reduction

A number of clinical trials have tested the use of aromatase inhibitors (AIs) in the adjuvant therapy of postmenopausal women with invasive breast cancer to reduce risk of recurrence. The first of these studies, the ATAC trial, randomized postmenopausal women with invasive breast cancer to anastrozole versus tamoxifen versus anastrozole plus tamoxifen in a double-blinded fashion. The occurrence of contralateral second primary breast cancers was a study endpoint. At 47 months median follow-up, a nonsignificant reduction in contralateral breast cancers was observed in women treated with anastrozole alone compared with tamoxifen (OR, 0.62; 95% CI, 0.38–1.02; \( P = .062 \)), and a significant reduction in contralateral breast cancers was seen in the subset of women with hormone receptor-positive first cancers (OR, 0.56; 95% CI, 0.32–0.98; \( P = .04 \)). Similar reductions in the risk for contralateral breast cancer have been observed with sequential tamoxifen followed by exemestane compared with tamoxifen alone and with sequential tamoxifen followed by letrozole compared with tamoxifen followed by placebo.

In the Breast International Group (BIG) 1-98 trial postmenopausal women with early-stage breast cancer were randomized to receive 5 years of treatment with one of the following therapeutic regimens: letrozole; sequential letrozole followed by tamoxifen; tamoxifen; or sequential
tamoxifen followed by letrozole. Risk for breast cancer recurrence was lower in women in the letrozole arm relative to the tamoxifen arm.\textsuperscript{135}

The results of the MAP.3 trial show promising use of exemestane in the breast cancer prevention setting. MAP.3 is a randomized, double-blind, placebo-controlled, multicenter, multinational trial in which 4560 women were randomly assigned to either exemestane (2285 patients) or placebo (2275 patients).\textsuperscript{4} The study authors reported that about 5\% of patients in each group had discontinued the protocol treatment. The major reasons for early discontinuation of the protocol treatments were toxic effects (15.4\% in the exemestane group vs. 10.8\% in the placebo group, $P < .001$) and patient refusal (6.9\% vs. 6.0\%, $P = .22$). After a median follow-up of 3 years, compared to the placebo exemestane was found to reduce the relative incidence of invasive breast cancers by 65\%, from 0.55\% to 0.19\% (HR, 0.35 with exemestane; 95\% CI, 0.18–0.70).\textsuperscript{4}

Similarly, the IBIS-II trial evaluated the role of anastrozole for breast cancer prevention. The IBIS-II study included 3864 postmenopausal women at high risk for breast cancer, defined by family history of breast cancer or prior diagnosis of DCIS, LCIS, or ADH.\textsuperscript{5} (HR, 0.47; 95\% CI, 0.32–0.68). The advantage of anastrozole was greater prevention of high-grade tumors (HR, 0.35; 95\% CI, 0.16–0.74) compared with intermediate- or low-grade tumors. The follow-up period in this trial was longer than that for the MAP.3 trial. The cumulative incidence after 7 years was predicted to rise 2.8\% in the anastrozole group compared with 5.6\% in the placebo group.\textsuperscript{5}

There are retrospective data that AIs can reduce the risk of contralateral breast cancer in \textit{BRCA-1/2} patients with ER-positive breast cancer who take AIs as adjuvant therapy.\textsuperscript{136}

\textbf{NCCN Breast Cancer Risk Reduction Panel Recommendations for Risk-Reduction Agents}

Based on data from the BCPT\textsuperscript{100} and STAR\textsuperscript{102} trials, Freedman et al have developed tables of benefit/risk indices for women aged 50 years and older to compare raloxifene versus no treatment (placebo) and tamoxifen versus no treatment.\textsuperscript{3} The risk and benefit of treatment with either tamoxifen or raloxifene depends on age, race, breast cancer risk, and history of hysterectomy. There are separate tables in the report listing the level of 5-year invasive breast cancer risk by age group for non-Hispanic white women with and without a uterus, black women with and without a uterus, and Hispanic women with and without a uterus. The NCCN Breast Cancer Risk Reduction Panel recommends using these tables\textsuperscript{3} while counseling postmenopausal women regarding use of raloxifene and tamoxifen for breast cancer risk reduction. It should be noted that these tables do not consider the greater risk reduction achieved in women with proliferative breast lesions such as AH.

\textbf{Tamoxifen Recommendations}

The NCCN Breast Cancer Risk Reduction Panel recommends tamoxifen (20 mg/d) as an option to reduce breast cancer risk in healthy pre- and postmenopausal women $\geq 35$ years of age, whose life expectancy is $\geq 10$ years, and who have a $\geq 1.7\%$ 5-year risk for breast cancer as determined by the modified Gail model, or who have had LCIS (category 1). The consensus of the NCCN Breast Cancer Risk Reduction Panel is that the risk/benefit ratio for tamoxifen use in premenopausal women at increased risk for breast cancer is relatively favorable (category 1), and that the risk/benefit ratio for tamoxifen use in postmenopausal women is influenced by age, presence of uterus, or other comorbid conditions (category 1). Early studies suggest that lower doses of tamoxifen over shorter treatment periods may reduce breast cancer risk in postmenopausal women, but these findings need to be validated in phase III clinical trials.\textsuperscript{137} Only limited
data are currently available regarding the efficacy of tamoxifen risk reduction in BRCA1/2 mutation carriers and women who have received prior thoracic radiation; there are no prospective studies evaluating the risk-reductive effect of tamoxifen in women with BRCA mutations. However, available data from a very small cohort suggest a benefit for women with a BRCA2 mutation but possibly not for women with a BRCA1 mutation.\(^{113}\)

The utility of tamoxifen as a breast cancer risk-reduction agent in women <35 years of age is not known. Tamoxifen is a teratogen and is contraindicated during pregnancy or in women planning a pregnancy. There are insufficient data on the influence of ethnicity and race on the efficacy and safety of tamoxifen as a risk-reduction agent.

There is evidence that certain drugs (eg, selective serotonin reuptake inhibitors [SSRIs]) interfere with the enzymatic conversion of tamoxifen to endoxifen by inhibiting a particular isoform of cytochrome P450 2D6 (CYP2D6) enzyme involved in the metabolism of tamoxifen.\(^{138}\) The consensus of the NCCN Breast Cancer Risk Reduction Panel is that alternative medications that have minimal or no impact on plasma levels of endoxifen should be substituted when possible.\(^{138}\) Citalopram and venlafaxine do not disrupt tamoxifen metabolism.

It has also been reported that certain CYP2D6 genotypes are markers of poor tamoxifen metabolism.\(^{139,140}\) Nevertheless, the consensus of the NCCN Breast Cancer Risk Reduction Panel is that further validation of this biomarker is needed before it can be used to select patients for tamoxifen therapy.

**Raloxifene Recommendations**

The NCCN experts serving on the Breast Cancer Risk Reduction Panel feel strongly that tamoxifen is a superior choice of risk-reduction agent for most postmenopausal women desiring non-surgical risk-reduction therapy. This is based on the updated STAR trial results that showed diminished benefits of raloxifene compared to tamoxifen after cessation of therapy.\(^{103}\)

However, consideration of toxicity may still lead to the choice of raloxifene over tamoxifen in some women.

If raloxifene is chosen, the NCCN Breast Cancer Risk Reduction Panel recommends use of 60 mg/d. Data regarding use of raloxifene to reduce breast cancer risk is limited to healthy postmenopausal women ≥35 years who have a ≥1.7% 5-year risk for breast cancer as determined by the modified Gail model, or who have a history of LCIS. The consensus of the NCCN Breast Cancer Risk Reduction Panel is that the risk/benefit ratio for raloxifene use in postmenopausal women at increased risk for breast cancer is influenced by age and comorbid conditions (category 1). There are no currently available data regarding the efficacy of raloxifene risk reduction in BRCA1/2 mutation carriers and women who have received prior thoracic radiation. Use of raloxifene to reduce breast cancer risk in premenopausal women is inappropriate unless part of a clinical trial. The utility of raloxifene as a breast cancer risk-reduction agent in women <35 years of age is not known. There are insufficient data on the influence of ethnicity and race on the efficacy and safety of raloxifene as a risk-reduction agent.

Overall, risk-reduction therapy with tamoxifen and raloxifene has been vastly underutilized.\(^{141}\) Women in whom the benefits of risk-reduction therapy far outweigh harms include those with AH (both ductal and lobular types) and LCIS.\(^{67,100}\) Women with AH and LCIS have a significantly higher risk of developing invasive breast cancer. The initial and follow-up results of the P-1 study (described in sections above) demonstrated a significant risk reduction in women with AH with tamoxifen therapy.\(^{100,101}\) Despite this, a study has documented that only 44% of women with AH or LCIS
received risk-reduction therapy. Considering the opportunity that exists for a significant impact of risk-reduction therapy on reducing the incidence of breast cancer, the NCCN Panel strongly recommends risk-reduction therapy in women with AH.

**AI Recommendations (Anastrozole and Exemestane)**

The NCCN experts serving on the Breast Cancer Risk Reduction Panel have included exemestane and anastrozole as choices of risk-reduction agent for most postmenopausal women desiring non-surgical risk-reduction therapy (category 1). This is based on the results of the MAP.3 trial and the IBIS-II trial. The NCCN Breast Cancer Risk Reduction Panel recommends use of 25 mg/d of exemestane or 1 mg/d of anastrozole. Data regarding use of AI (exemestane and anastrozole) to reduce breast cancer risk are limited to postmenopausal women 35 years of age or older with a Gail model 5-year risk score >1.66% or a history of LCIS. The consensus of the NCCN Breast Cancer Risk Reduction Panel is that the risk/benefit ratio for use of an AI in postmenopausal women at increased risk for breast cancer is influenced by age, bone density, and comorbid conditions. Use of an AI to reduce breast cancer risk in premenopausal women is inappropriate unless part of a clinical trial. The utility of an AI as a breast cancer risk-reduction agent in women <35 years of age is not known. There are insufficient data on the influence of ethnicity and race on the efficacy and safety of AIs as a risk-reduction agent.

Exemestane and anastrazole are not currently FDA approved for breast cancer risk reduction. Currently, there are no data comparing the benefits and risks of AI to those of tamoxifen or raloxifene.

**Monitoring Patients on Risk Reduction Agents**

Follow-up of women treated with risk-reduction agents for breast cancer risk reduction should focus on the early detection of breast cancer and the management of adverse symptoms or complications. Appropriate monitoring for breast cancer and the evaluation of breast abnormalities should be performed according to the guidelines described for high-risk women in the NCCN Guidelines for Breast Cancer Screening and Diagnosis. The population of women eligible for risk-reduction therapy with tamoxifen, raloxifene, anastrozole, or exemestane is at sufficiently increased risk for breast cancer to warrant, at a minimum, yearly bilateral mammography with consideration for tomosynthesis, a clinical breast examination every 6 to 12 months, and encouragement of breast awareness. Supplemental screening with breast MRI may be indicated for certain women at increased risk of breast cancer (see NCCN Guidelines for Breast Cancer Screening and Diagnosis).

**Endometrial Cancer**

Results from the P-1 study indicated that women ≥50 years of age treated with tamoxifen have an increased risk of developing invasive endometrial cancer. For women ≥50 years the risk of developing endometrial cancer while on tamoxifen compared to placebo was increased (RR, 4.01; 95% CI, 1.70–10.90). An increased risk for endometrial cancer was not observed in women ≤49 years of age treated with tamoxifen in this study (RR, 1.21; 95% CI, 0.41–3.60). Although the only death from endometrial cancer in the P-1 study occurred in a placebo-treated subject, analyses of the NSABP data have revealed a small number of uterine sarcomas among the number of patients with an intact uterus taking tamoxifen. Uterine sarcoma is a rare form of uterine malignancy reported to occur in 2% to 4% of all patients with uterine cancer. Compared with other uterine cancers, uterine sarcomas present at a more advanced stage and thus may carry a worse prognosis in terms of disease-free and overall survival.
Updated results from the NSABP studies have indicated that incidence of both endometrial adenocarcinoma and uterine sarcoma is increased in women taking tamoxifen when compared to the placebo arm.\textsuperscript{145} Several other studies have also supported an association between tamoxifen therapy and an increased risk of developing uterine sarcoma.\textsuperscript{143,144,146,147} A “black box” FDA warning has been included on the package insert of tamoxifen to highlight the endometrial cancer risk (both epithelial endometrial cancer and uterine sarcoma) of tamoxifen.\textsuperscript{148} Nonetheless, the absolute risk of developing endometrial cancer is low (absolute annual risk per 1000: placebo 0.91 vs. tamoxifen 2.30). Often, for women at increased risk for breast cancer, the reduction in the number of breast cancer events exceeds that of the increase in the number of uterine cancer events.

Use of raloxifene has not been associated with an increased incidence of endometrial cancer in the MORE trial.\textsuperscript{126} Long-term results from the STAR trial showed the incidence of invasive endometrial cancer to be significantly lower in the group receiving raloxifene compared with the tamoxifen group (RR, 0.55; CI, 0.36–0.83).\textsuperscript{103}

For women with an intact uterus, a baseline gynecologic assessment is recommended prior to administration of tamoxifen, and follow-up gynecologic assessments should be performed at each visit.\textsuperscript{149} The vast majority of women with tamoxifen-associated endometrial cancer present with vaginal spotting as an early symptom of cancer. Therefore, prompt evaluation of vaginal spotting in the postmenopausal woman is essential.

At present, there is insufficient evidence to recommend the performance of uterine ultrasonography or endometrial biopsy for routine screening in asymptomatic women.\textsuperscript{150-152} In women diagnosed with endometrial cancer while taking a risk-reduction agent, the drug should be discontinued until the endometrial cancer has been fully treated. The NCCN Breast Cancer Risk Reduction Panel believes that it is safe and reasonable to resume therapy with a risk-reduction agent after completion of treatment for early-stage endometrial cancer.

**Retinopathy and Cataract Formation**

There have been reports of tamoxifen being associated with the occurrence of retinopathy, although most of this information has come from case studies.\textsuperscript{153,154} Furthermore, these reports have not been confirmed in the randomized controlled trials of tamoxifen. A 1.14 RR of cataract formation (95% CI, 1.01–1.29), compared with placebo, has been reported in the P-1 study, and individuals developing cataracts while on tamoxifen have an RR for cataract surgery of 1.57 (95% CI, 1.16–2.14), compared with placebo.\textsuperscript{100} After 7 years of follow-up in the P-1 study, RRs of cataract formation and cataract surgery were similar to those initially reported.\textsuperscript{101} In the MORE trial, raloxifene use was not associated with an increase in the incidence of cataracts compared with placebo (RR, 0.9; 95% CI, 0.8–1.1).\textsuperscript{155} In the STAR trial, the incidence of cataract development and occurrence of cataract surgery were significantly higher in the group receiving tamoxifen compared with the group receiving raloxifene.\textsuperscript{103,155} The rate of cataract development (RR, 0.80; 95% CI, 0.72–0.89) and the rate of cataract surgery (RR, 0.79; 95% CI, 0.70–0.90) were about 20% less in the raloxifene group than in the tamoxifen group.\textsuperscript{103,155} Thus, patients experiencing visual symptoms while undergoing treatment with tamoxifen should seek ophthalmologic evaluation.

**Bone Mineral Density**

Bone is an estrogen-responsive tissue, and tamoxifen can act as either an estrogen agonist or estrogen antagonist with respect to bone, depending on the menstrual status of a woman.\textsuperscript{115,156-158} In premenopausal women, tamoxifen may oppose the more potent effects of estrogen on the bone and potentially increase the risk for osteoporosis, whereas tamoxifen in the presence of typically lower estrogen levels in postmenopausal women
is associated with an increase in BMD. However, the NCCN Breast Cancer Risk Reduction Panel does not recommend monitoring BMD in premenopausal patients on tamoxifen, since development of osteopenia/osteoporosis in this population is considered unlikely.

Raloxifene has been shown to increase BMD and to reduce incidence of vertebral bone fracture in postmenopausal women when compared with placebo. Results from the STAR trial did not reveal any difference in the incidence of bone fracture in the groups of postmenopausal women on either raloxifene or tamoxifen.

Changes in BMD are of concern in women on AI therapy. Therefore, a baseline BMD scan is recommended for post-menopausal women before initiating therapy with an AI such as anastrozole or exemestane.

Thromboembolic Disease and Strokes
Tamoxifen and raloxifene have been associated with an increased risk of thromboembolic events (ie, DVT, pulmonary embolism) and stroke. Increased incidences of VTE were observed in the tamoxifen arms of all the placebo-controlled, randomized, risk-reduction trials. Although not statistically significant, all of these trials with the exception of the Royal Marsden trial (which enrolled only younger women) also showed an increase in risk for stroke for women receiving tamoxifen. This risk was found to be significantly elevated in 2 meta analyses of randomized controlled trials evaluating tamoxifen for breast cancer risk reduction or treatment. Comparison of the raloxifene and tamoxifen arms of the STAR trial did not show a difference with respect to incidence of stroke, and the risk of fatal stroke was significantly higher for women in the RUTH trial with underlying heart disease receiving raloxifene. However, evidence has shown that women with a Factor V Leiden or prothrombin mutations or intermittent screening of women for thromboembolic disease is unlikely to be of value, women taking tamoxifen or raloxifene should be educated regarding the symptoms associated with DVT and pulmonary emboli. They should also be informed that prolonged immobilization may increase risk of VTE, and they should be instructed to contact their physicians immediately if they develop symptoms of DVT or pulmonary emboli. Women with documented thromboembolic disease should receive appropriate treatment for the thromboembolic condition and should permanently discontinue tamoxifen or raloxifene therapy.

Managing Side Effects of Risk-Reduction Agents
Hot flashes are a common menopausal complaint. In the P-1 study, hot flashes occurred in approximately 81% of women treated with tamoxifen and 69% of women treated with placebo. In the STAR trial, women receiving tamoxifen reported a significantly increased incidence of vasomotor symptoms relative to women receiving raloxifene, although raloxifene use has also been associated with an increase in hot flash severity and/or frequency when compared with placebo. In women whose quality of life is diminished by hot flashes, an intervention to eliminate or minimize hot flashes should be undertaken. Estrogens and/or progestins have the potential to interact with SERMs and are not recommended by the NCCN Breast Cancer Risk Reduction Panel for the treatment of hot flashes for women on a risk-reduction agent outside of a clinical trial.

Gabapentin, a gamma-aminobutyric acid (GABA) analog used primarily for seizure control and management of neuropathic pain, has been reported to moderate both the severity and duration of hot flashes. It has been hypothesized that the mode of action of gabapentin is via central
Results from a randomized, double-blind, placebo-controlled study involving the use of gabapentin to treat hot flashes in 420 women with breast cancer have been reported. The three treatment arms of the trial were as follows: 300 mg/d gabapentin; 900 mg/d gabapentin; and placebo. Study duration was 8 weeks, and most of the women in the study (68%–75% depending on treatment arm) were taking tamoxifen as adjuvant therapy. Women in the placebo group experienced reductions in severity of hot flashes of 21% and 15% at 4 and 8 weeks, respectively, whereas those in the treatment arms reported reductions of 33% and 31% with lower-dose gabapentin, and 49% and 46% with higher-dose gabapentin at 4 and 8 weeks, respectively. Only women receiving the higher dose of gabapentin had significantly fewer and less severe hot flashes. Side effects of somnolence or fatigue were reported in a small percentage of women taking gabapentin.

Venlafaxine, a serotonin and norepinephrine inhibitor anti-depressant, has been shown to be effective in the management of hot flash symptoms in a group of breast cancer survivors, 70% of whom were taking tamoxifen. Significant declines were observed for both hot flash frequency and severity scores for all doses of venlafaxine (37.5 mg, 75 mg, and 150 mg) compared to placebo; incremental improvement was seen at 75 mg versus 37.5 mg ($P = .03$). Participants receiving venlafaxine reported mouth dryness, reduced appetite, nausea, and constipation with increased prevalence at increased dosages. Based on these findings the authors suggested a starting dose of 37.5 mg with an increase, as necessary after one week, to 75 mg if a greater degree of symptom control is desired. However, this study followed subjects for only 4 weeks.

Another antidepressant, paroxetine, an SSRI, has also been studied for the relief of hot flash symptoms. A double-blind, placebo-controlled trial recruited 165 menopausal women who were randomized into 3 arms (placebo, paroxetine 12.5 mg daily, or paroxetine 25 mg daily). After 6 weeks, significant reductions in composite hot flash scores were noted for both dosages of paroxetine (12.5 mg, 62% reduction and 25 mg, 65% reduction), there were no significant differences between dose levels. Adverse events, reported by 54% of subjects receiving placebo and 58% receiving paroxetine, generally included nausea, dizziness, and insomnia.

In a stratified, randomized, double-blind, cross-over, placebo-controlled study, 151 women reporting a history of hot flashes were randomized to one of 4 treatment arms (10 mg or 20 mg of paroxetine for 4 weeks followed by 4 weeks of placebo or 4 weeks of placebo followed by 4 weeks of 10 mg or 20 mg of paroxetine). Hot flash frequency and composite score were reduced by 40.6% and 45.6%, respectively, for patients receiving 10 mg paroxetine compared to reductions of 13.7% and 13.7% in the placebo group. Likewise, reductions of 51.7% and 56.1% in hot flash frequency and score were found in women receiving 20 mg paroxetine compared with values of 26.6% and 28.8% in the placebo group. No significant differences in efficacy were observed with the lower and higher paroxetine doses. Rates of the most commonly reported side effects did not differ among the 4 arms, although nausea was significantly increased in women receiving 20 mg paroxetine relative to the other arms, and a greater percentage of patients receiving the higher dose of paroxetine discontinued treatment.

While these reports appear promising, further randomized studies of the use of these agents in women experiencing hot flash symptoms, especially those also taking tamoxifen, are needed to assess the long-term effectiveness and safety of these agents. In this context it should be noted that evidence has suggested that concomitant use of tamoxifen with certain SSRIs (eg, paroxetine and fluoxetine) may...
decrease plasma levels of endoxifen and 4-OH tamoxifen, active metabolites of tamoxifen, and may impact its efficacy. These SSRIs may interfere with the enzymatic conversion of tamoxifen to its active metabolites by inhibiting a particular isoform of cytochrome P-450 enzyme (CYP2D6) involved in the metabolism of tamoxifen. Caution is advised about co-administration of these drugs with tamoxifen. Citalopram and venlafaxine appear to have only minimal effects on tamoxifen metabolism.

Of interest in this context are results of a retrospective evaluation of data from the Women’s Healthy Eating and Living (WHEL) randomized trial, which suggest an inverse association between hot flashes and breast cancer recurrence for women with a history of breast cancer receiving tamoxifen. These results suggest that hot flashes in women receiving tamoxifen may be an indicator of the biologic availability and, thus, effectiveness of the drug. However, additional studies are needed to further elucidate whether hot flashes are predictive of benefit from tamoxifen.

A report of two nonrandomized, parallel study cohorts of women with DCIS or those at high risk for breast cancer (eg, those with LCIS; AH, or ≥1.7% 5-year breast cancer risk by the Gail model) comparing women receiving tamoxifen alone with women receiving tamoxifen concomitantly with HT (mean duration of HT at start of study was approximately 10 years) did not show a difference in the rate of tamoxifen-induced hot flashes. The NCCN Breast Cancer Risk Reduction Panel recommends against the use of HT for women taking tamoxifen or raloxifene outside of a clinical trial.

A variety of other substances for the control of hot flashes have been described. Both the oral and transdermal formulations of clonidine reduce hot flashes in a dose-dependent manner. Toxicities associated with clonidine include dry mouth, constipation, and drowsiness. Anecdotal evidence suggests that the use of a number of different herbal or food supplements may alleviate hot flashes. Vitamin E may decrease the frequency and severity of hot flashes, but results from a randomized clinical trial demonstrated that only a very modest improvement in hot flashes was associated with this agent compared with placebo. Results from a double-blind, randomized, placebo-controlled, crossover trial of the use of black cohosh to treat hot flashes did not show significant differences between groups with respect to improvement in hot flash symptoms. Some herbal or food supplements contain active estrogenic compounds, the activity and safety of which are unknown. Other strategies such as relaxation training, acupuncture, avoidance of caffeine and alcohol, and exercise for the management of hot flashes, while potentially beneficial, remain unsupported.

It should be noted that the observed placebo effect in the treatment of hot flashes is considerable, typically falling in the range 25% or more, suggesting that a considerable proportion of patients might be helped through a trial of therapy of limited duration. However, not all women who experience hot flashes require medical intervention, and the decision to intervene requires consideration of the efficacy and toxicity of the intervention. In addition, a study of women receiving tamoxifen for early-stage breast cancer showed a decrease in hot flashes over time.

Weight-bearing exercise or use of a bisphosphonate (oral/IV) or denosumab is acceptable to maintain or to improve BMD and reduce risk of fractures in postmenopausal women.

Components of Risk-Reduction Counseling
Women should be monitored according to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. Women with known or suspected BRCA1/2, TP53, PTEN, or other gene mutations associated with breast cancer risk or those with a significant family history of breast and/or
ovarian cancer should also be followed according to the NCCN Guidelines for Genetic/Familial High-Risk Assessment: Breast and Ovarian whether or not they choose to undergo risk-reduction therapy. Women who have abnormal results from their clinical breast examination or bilateral mammogram or those with a history of LCIS should be managed according to the NCCN Guidelines for Breast Cancer Screening and Diagnosis. All women who are appropriate candidates for breast cancer risk-reduction intervention should undergo counseling that provides a description of the available strategies, including a healthy lifestyle, to decrease breast cancer risk. Options for breast cancer risk reduction should be discussed in a shared decision-making environment. The counseling should include a discussion and consideration of: 1) the individual's overall health status, including menopausal status, medical history, and medication history (eg, hysterectomy status, prior history of VTE, current use of hormones or SSRIs, previous use of a SERM); 2) absolute and relative breast cancer risk reduction achieved with the risk-reduction intervention; 3) risks of risk-reduction therapy with an emphasis on age-dependent risks; 4) the contraindications to therapy with tamoxifen and raloxifene (eg, history of VTE, history of thrombotic stroke, history of transient ischemic attack, pregnancy or pregnancy potential without an effective nonhormonal method of contraception); and 5) the common and serious side effects of tamoxifen and raloxifene.

The 2009 ASCO Guidelines comparing the effectiveness of breast cancer risk-reduction agents provide some estimates of either the number needed to treat (NNT) to prevent breast cancer or the number needed to harm (NNH) by causing a specific side effect in a single patient receiving a specific risk-reduction agent. Both NNT and NNH can be useful aids in communicating risks and benefits of tamoxifen and raloxifene in this setting (eg, using long-term data from the IBIS-1 trial, NNH with respect to VTE was determined to be 73 with tamoxifen, whereas this value was 150 for patients receiving raloxifene using data from the RUTH study).

**Counseling Prior to Therapy with Risk-Reduction Agents**

Counseling sessions with women who are considering non-surgical breast cancer risk reduction should incorporate an explanation of data from the P-1, STAR, MAP, and/or IBIS-II trial as appropriate.

Germline mutations in PTEN occur in 85% of patients with Cowden syndrome, an inherited condition associated with increased endometrial carcinoma risk. Therefore, increased risk for endometrial cancer in women with PTEN mutations should be discussed while considering tamoxifen.

**Counseling on Use of a SERM for Breast Cancer Risk Reduction**

The P-1 study showed that the toxicity profile of tamoxifen is much more favorable in younger women, and the benefits in RR reduction are similar across all age groups and risk groups. The tamoxifen treatment risk/benefit ratio is especially favorable in women between the ages of 35 and 50 years. Unfortunately, individualized data regarding the risk/benefit ratio for tamoxifen are not generally available except for the broad age categories of ages 50 years and younger versus older than 50 years of age. Tamoxifen, unlike raloxifene, is a risk-reduction agent that can be used by premenopausal women. In addition, tamoxifen may be more effective than raloxifene in reducing the incidence of noninvasive breast cancer, although the difference is not statistically significant at long-term follow-up. Further, tamoxifen was reported by patients in the STAR trial to be associated with better sexual function than raloxifene. However, tamoxifen has been associated with an increased incidence of invasive endometrial cancer relative to placebo in women ≥50 years of age, and an increased incidence of endometrial hyperplasia and invasive endometrial cancer relative to raloxifene, possibly making it a less attractive choice in women with a uterus. Use of raloxifene to reduce
breast cancer risk may be preferred by postmenopausal women with a uterus or those at risk for developing cataracts. All women receiving a breast cancer risk-reduction agent should be counseled with respect to signs and symptoms of possible side effects associated with use of these agents, and the recommended schedules for monitoring for the presence of certain adverse events. Contraindications to tamoxifen or raloxifene include history of VTE, thrombotic stroke, transient ischemic attack, current pregnancy or pregnancy potential without effective method of contraception, or known inherited clotting trait.

The optimal duration of SERM therapy for breast cancer risk reduction is not known. The P-1 and STAR trials studied 5 years of risk-reduction therapy with either tamoxifen or raloxifene. However, based on the updated STAR results, which showed that the benefits of raloxifene diminished after cessation of therapy, continuing raloxifene beyond 5 years might be an approach to maintain the risk-reduction activity of the agent.

The use of tamoxifen for periods longer than 5 years has been evaluated in the adjuvant treatment setting. Results of two randomized trials on extended adjuvant tamoxifen treatment have demonstrated that tamoxifen for up to 10 years is more effective than shorter durations at preventing cancer recurrence and improving breast cancer survival. The option of 10 years of adjuvant tamoxifen therapy is now recommended for both premenopausal women and postmenopausal women for preventing cancer recurrence in the NCCN Guidelines for Breast Cancer and the ASCO Guidelines. There are limited data on tamoxifen use for more than 5 years in the risk-reduction setting. Until further information is available, a period of 5 years appears to be appropriate for tamoxifen therapy when the agent is used to reduce breast cancer risk.

After completing 5 years of tamoxifen therapy, women should continue to be monitored according to the NCCN Guidelines for Breast Cancer Screening and Diagnosis and should continue to undergo monitoring for late toxicity, especially for endometrial cancer and cataracts.

The prolonged effectiveness of tamoxifen as an agent to reduce breast cancer risk, particularly with respect to the development of ER-positive disease, is supported by results of several placebo-controlled, randomized trials at long-term follow-up. The results from the STAR trial suggest that although a 5-year course of raloxifene retains considerable benefit with respect to the prevention of invasive breast cancer at a median follow-up of 81 months, the breast cancer preventive benefit of 5 years of tamoxifen therapy is significantly greater.

The NCCN Breast Cancer Risk Reduction Panel recommends using the tables from the Freedman et al publication while counseling postmenopausal women regarding use of raloxifene and tamoxifen for breast cancer risk reduction.

Counseling on Use of an AI for Breast Cancer Risk Reduction
Currently, there are no data comparing the benefits and risks of AIs (exemestane or anastrozole) to those of tamoxifen or raloxifene. Data regarding exemestane are from the single, large, randomized MAP.3 trial limited to postmenopausal women 35 years of age or older with a Gail model 5-year breast cancer risk of 1.7% or a history of LCIS, which may be used while counseling patients. The data show that exemestane has a completely different toxicity profile than the SERMs. Compared to the placebo group in the MAP.3 trial, exemestane had no increased risk of serious side effects. The incidence of osteoporosis, cardiac events, and bone fractures were identical for women in the MAP.3 trial taking exemestane and for those taking the placebo. However, follow-up was only 35 months. Women taking exemestane had a small, but not
A statistically significant increase in menopausal symptoms, such as hot flashes (18.3% vs. 11.9%) and arthritis (6.5% vs. 4.0%).

Data regarding anastrozole are from a single, large, randomized trial, IBIS-II. The trial included postmenopausal women 40 to 70 years of age with a higher risk of developing cancer compared with the general population. Women who did not meet these criteria but had a Tyrer-Cuzick model 10-year breast cancer risk >5% were also included. Musculoskeletal and vasomotor events were reported in both arms of the trial and were found to be significantly higher in the anastrozole arm ($P = 0.0001$); fracture rates were similar in both arms. The optimal duration of AI therapy is currently unknown. Changes in BMD are of concern in women receiving AI therapy. Therefore, a baseline BMD scan is recommended before initiating exemestane therapy. The role of calcium, vitamin D, and a healthy lifestyle in maintaining bone health must be emphasized in healthy postmenopausal women who are receiving exemestane.

Counseling Prior to Risk Reduction Surgery

For women at very high risk for breast cancer who are considering RRM, it is important that the potential psychosocial effects of RRM are addressed, although these effects have not been well studied. Such surgery has the potential to negatively impact perceptions of body image, ease of forming new relationships, and the quality of existing relationships. Moreover, the procedure also eliminates the breast as a sexual organ. Multidisciplinary consultations are recommended prior to surgery, and should include a surgeon familiar with the natural history and therapy of benign and malignant breast disease to enable the woman to become well informed regarding treatment alternatives, the risks and benefits of surgery, nipple-sparing mastectomy, and surgical breast reconstruction options. Immediate breast reconstruction is an option for many women following RRM, and early consultation with a reconstructive surgeon is recommended for those considering either immediate or delayed breast reconstruction. Psychological consultations may also be considered.

Discussions regarding the risk for ovarian cancer and the option of risk reducing salpingo-oophorectomy (RRSO) for breast and ovarian cancer risk reduction should also be undertaken with women who are known carriers of a BRCA1/2 mutation. Other topics that should be addressed with respect to RRSO include the increased risk for osteoporosis and cardiovascular disease associated with premature menopause, as well as the potential effects of possible cognitive changes, accelerated bone loss, and vasomotor symptoms on quality of life. Furthermore, the surgery itself may have some associated complications.

It has been reported that short-term HT in women undergoing RRSO did not negate the reduction in breast cancer risk associated with the surgery. In addition, results of a case-control study of BRCA1 mutation carriers showed no association between use of HT and increased breast cancer risk in postmenopausal BRCA1 mutation carriers. However, the consensus of the NCCN Breast Cancer Risk Reduction Panel is that caution should be used when considering HT use in mutation carriers following RRSO, given the limitations inherent in nonrandomized studies (see also section below on Breast Cancer Risks Associated with Hormone Therapy). It is unlikely that a prospective randomized study on the use of RRSO for breast cancer risk reduction will be performed. Whether the resulting reduction in the risk for breast cancer from this procedure is preferable to an RRM is likely to remain a personal decision. Table 2 provides estimates based on a Monte Carlo simulation model of the survival impact of breast and ovarian risk-reduction strategies. These data can be used as a tool to facilitate shared decision-making regarding choice of a risk-reduction approach, particularly with respect to issues related to risk-reduction surgery (see Table 2).
Counseling Regarding Lifestyle Modifications

There is evidence to indicate that certain lifestyle characteristics, such as obesity, increased alcohol consumption, and use of certain types of HT, are factors or markers for an elevated risk for breast cancer. However, the association between a lifestyle modification and a change in breast cancer risk is not as clear. Nevertheless, a discussion of lifestyle characteristics associated with increased risk for breast cancer also provides “a teachable moment” for the promotion of overall health, and an opportunity to encourage women to make choices and changes compatible with a healthy lifestyle.

Breast Cancer Risks Associated with Hormone Therapy

The Women’s Health Initiative (WHI) enrolled 161,809 postmenopausal women 50 to 79 years of age into a set of clinical trials from 1993 through 1998. Two of these trials were randomized controlled studies involving the use of HT (estrogen with/without progestin) in primary disease prevention: a trial involving 16,608 women with intact uteri at baseline randomized to receive estrogen plus progestin or placebo, and a trial of 10,739 women with prior hysterectomy randomized to receive estrogen alone or placebo. The former trial was terminated early due to evidence of breast cancer harm, along with a global index associated with overall harm. In that study, a 26% increased incidence of breast cancer was observed in the treatment group (HR, 1.26; 95% CI, 1.00–1.59). An increased incidence of abnormal mammograms was also observed for women in the WHI who received estrogen plus progestin, and was attributed to an increase in breast density. Of greater concern is that HT was associated with a significant increase in rates of both breast cancer incidence and breast cancer-related mortality, although the increased risk for breast cancer rapidly declined following cessation of HT.

An increased risk for breast cancer was not observed in the trial of women who had undergone hysterectomies and were receiving unopposed estrogen. In fact, the rate of breast cancer was lower in the group receiving estrogen relative to the placebo group, although this difference was not considered to be statistically significant. The lower incidence of breast cancer seen among women randomized to estrogen alone during the intervention period became statistically significant with extended follow-up for a mean of 10.7 years. However, an increased incidence of abnormal mammograms was observed in the group of women receiving estrogen, as well as a doubling of the risk for benign proliferative breast disease.

Analysis of the data from this randomized controlled WHI trial showed use of estrogen alone to significantly increase mammographic breast density compared with women receiving placebo; this effect was observed for at least a 2-year period. Contrary to the results from the WHI randomized controlled trials, results from several prospective, population-based, observational studies have shown use of estrogen-only HT to be associated with increased risks for breast cancer. These studies include the Black Women’s Health Study where use of estrogen alone for a duration of 10 years or longer was associated with a nonsignificant increase in risk for invasive breast cancer (RR = 1.41; 95% CI, 0.95–2.10); the Million Women Study of women 50 to 64 years of age, which showed an association between current use of estrogen-only HT and increased risk for breast cancer (RR = 1.30; 95% CI, 1.21–1.40; P < .0001); and the Nurses’ Health Study, which demonstrated a significantly increased breast cancer risk after long-term use (20 years or longer) of estrogen alone (RR, 1.42; 95% CI, 1.13–1.77).

It has been noted that there are important differences in the populations enrolled in the WHI randomized clinical trials relative to the women followed in the observational studies with respect to duration of exposure to HT and age at initiation of HT. For example, many of the women in
the WHI clinical trials did not start receiving HT until years after menopause, whereas those in the population-based studies were more likely to initiate HT at menopause and to have been exposed to such treatment for longer periods of time. One hypothesis put forward to explain the apparent contradictions in the summary of studies of HT described above is that short-term use of estrogen following a period of estrogen deprivation may decrease breast cancer risk by inducing apoptosis of occult breast cancer tumors, whereas long-term use of estrogen may initiate and promote the growth of new tumors, thereby increasing breast cancer risk. However, further studies are needed to evaluate this hypothesis. Another possible explanation for the decrease in breast cancer risk observed in the first 2 years of the WHI randomized controlled trial of postmenopausal women receiving estrogen plus progestin may be related to HT effects on breast tissue and subsequent interference with the ability of mammography to detect new breast cancer tumors.

The use of estrogen/progestin therapy and estrogen therapy alone has also been associated with increased risk for cardiovascular disease (eg, stroke) and decreased risk for bone fractures. However, a secondary analysis from the WHI randomized controlled trials showed a trend for more effective reduction in the risk for cardiovascular disease with initiation of HT closer to menopause compared with administration of HT to women who experienced a greater time gap between menopause and the start of such therapy. Nevertheless, results from a large French cohort control study show a significantly increased risk for breast cancer in women receiving short-term (ie, 2 years or less) estrogen and progesterone shortly after menopause when compared with nonusers.

The NCCN Breast Cancer Risk Reduction Panel recommends against the use of HT for women taking tamoxifen, raloxifene, anastrozole, or exemestane outside of a clinical trial.

Alcohol Consumption

Numerous studies have demonstrated that the intake of moderate amounts of alcohol (1–2 drinks per day) is associated with an increased risk for breast cancer. A 10% increase in breast cancer risk for every 10 grams of alcohol consumed each day was seen in analyses of 2 cohort studies. A population-based study of 51,847 postmenopausal women provided evidence to support an association between increased alcohol consumption and an increased likelihood of development of ER-positive breast cancer. A meta-analysis of epidemiologic studies shows a small but significant association between breast cancer and light alcohol intake (RR, 1.05; 95% CI, 1.02–1.08). Even one drink per day modestly elevates breast cancer risk. However, the effect of a reduction in alcohol consumption on the incidence of breast cancer has not been well studied.

The consensus of the NCCN Breast Cancer Risk Reduction Panel is that alcohol consumption should be limited to <1 drink per day. The panel has defined one drink as 1 ounce of liquor, 6 ounces of wine, or 8 ounces of beer.

Exercise and BMI

Increased levels of physical activity have been associated with a decreased risk for breast cancer. For example, the effect of exercise on breast cancer risk was evaluated in a population-based study of 90,509 women between the ages of 40 and 65 years. An RR of 0.62 (95% CI, 0.49–0.78) was observed for women who reported more than 5 hours of vigorous exercise per week compared to women who did not participate in recreational activities. These results are supported by another population-based, case-control study of 4538 case patients with newly diagnosed invasive breast cancer and control patients grouped according to race (eg, 1605 black and 2933 white patients). Both black and white women with annual lifetime exercise activity levels exceeding...
the median activity level for active control subjects were found to have a 20% lower risk for breast cancer when compared to inactive women (OR, 0.82; 95% CI, 0.71–0.93). In addition, a prospective assessment evaluating the association of physical activity among 45,631 women showed the greatest reduction in breast cancer risk for women who reported walking/hiking for ≥10 hours per week (RR, 0.57; 95% CI, 0.34–0.95). A study of 320 postmenopausal sedentary women randomly assigned to 1 year of aerobic exercise or a control group showed modest but significant changes in serum levels of estradiol and sex hormone-binding globulin from baseline (ie, a decrease and an increase in these levels, respectively). However, it has been suggested that other, as yet unidentified, mechanisms are more likely to be responsible for the association between increased activity level and decreased risk for breast cancer.

As discussed under the section on Elements of Risk, here is a substantial amount of evidence indicating that overweight or obese women have a higher risk for postmenopausal breast cancer. Results from the Nurses’ Health Study evaluating the effect of weight change on the incidence of invasive breast cancer in 87,143 postmenopausal women suggested that women experiencing a weight gain of 25.0 kg or more since age 18 have an increased risk for breast cancer when compared with women who have maintained their weight (RR, 1.45; 95% CI, 1.27–1.66). Furthermore, women who had never used postmenopausal HT and lost 10.0 kg or more since menopause and kept the weight off had a significantly lower risk for breast cancer than women who had maintained their weight (RR, 0.43; 95% CI, 0.21–0.86). Interestingly, there is evidence that the risk for breast cancer is lower in premenopausal women who are overweight compared with women who are not overweight. Results from a case-control study of 1073 pairs of women with BRCA1/2 mutations indicated that a weight loss of 10 or more pounds in women with the BRCA1 mutation between the ages of 18 and 30 was associated with a decreased risk of developing breast cancer between the ages of 30 and 40 years. (OR, 0.35; 95% CI, 0.18–0.67).

Patients should be encouraged to exercise and stay active, and should be counseled on maintaining a healthy body weight and BMI.

Diet

While there is no clear evidence that specific dietary components can effectively reduce breast cancer risk, weight gain and obesity in adulthood are risk factors for the development of postmenopausal breast cancer. Results from a number of population-based studies have suggested that the effect of diet composition on breast cancer risk may be much greater during adolescence and early adulthood. In a prospective study of 993,466 women observed for 11 to 20 years, no association between total fruit and vegetable intake and overall risk of breast cancer was identified. However, there is some evidence of decreased breast cancer risk with a diet high in fruits and vegetables. A case-control study showed that a diet rich in fruits and vegetables may be associated with a decreased risk for breast cancer, including among women who were less physically active throughout their lifetimes. Epidemiologic studies suggest that vitamin D (from dietary sources and the sun) may play a protective role with respect to decreasing risk for breast cancer development. Furthermore, there is some evidence to suggest that such protection is greatest for women who had more prolonged skin exposure to sunlight and higher dietary intake of sources of vitamin D during adolescence. Studies are in progress to evaluate the role of vitamin D on breast cancer risk.
Other Lifestyle Changes
Counseling should also involve discussion of other factors that may have a protective effect, if appropriate, such as planning first childbirth at a younger age and encouraging breastfeeding.

Clinical Trials
Risk-reduction counseling should include a discussion of breast cancer risk-reduction interventions available in clinical trials.

Summary
Breast cancer risk assessment provides a means of identifying healthy women without a history of personal breast cancer, who are at increased risk for future development of this disease. All women should be counseled regarding healthy lifestyle recommendations to decrease breast cancer risk and to avoid lifestyles that would adversely impact their chance of developing the disease. However, many of the risk factors for breast cancer are not modifiable. The demonstration that tamoxifen, raloxifene, anastrozole, or exemestane substantially decreases the future risk for breast cancer provides an opportunity for a risk-reduction intervention.

The risks and benefits associated with use of risk-reduction agents for an individual woman should be evaluated and discussed with the woman as part of a shared decision-making process. Women in whom benefits of risk-reduction therapy significantly exceed the harms are those with AH or LCIS. Therefore, the NCCN Panel strongly recommends risk-reduction therapy in these women. Women taking a risk-reduction agent must be closely monitored for potential side effects associated with use of these agents. In special circumstances, such as in women who are carriers of a BRCA1/2 mutation, where the risk for breast cancer is very high, the performance of a bilateral mastectomy or BSO may be considered for breast cancer risk reduction. Women considering either surgery should undergo multidisciplinary consultations prior to surgery so as to become well informed about all treatment alternatives, the risks and benefits of risk-reduction surgery, and, in the case of bilateral mastectomy, the various reconstruction options available. The NCCN Guidelines for Breast Cancer Risk Reduction Panel strongly encourages women and health care providers to participate in clinical trials to test new strategies for decreasing the risk for breast cancer. Only through the accumulated experience gained from prospective and well-designed clinical trials will additional advances in breast cancer risk reduction be realized.
Table 1

Criteria Used in Calculation of 5-year Risk for Breast Cancer According to the Modified Gail Model  
(Available at [www.breastcancerprevention.org](http://www.breastcancerprevention.org))

<table>
<thead>
<tr>
<th>Question</th>
<th>Response</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td></td>
</tr>
<tr>
<td>Age at menarche (first menstrual period)</td>
<td></td>
</tr>
<tr>
<td>Age at first live birth or nulliparity</td>
<td></td>
</tr>
<tr>
<td>Number of breast biopsies</td>
<td></td>
</tr>
<tr>
<td>Atypical hyperplasia</td>
<td>Y / N</td>
</tr>
<tr>
<td>Number of first-degree relatives with breast cancer</td>
<td></td>
</tr>
<tr>
<td>Race/Ethnicity</td>
<td>Caucasian, African American, Hispanic, Other</td>
</tr>
<tr>
<td>Variable</td>
<td>Survival Probability (%) in BRCA1 Mutation Carriers</td>
</tr>
<tr>
<td>----------</td>
<td>------------------------------------------------------</td>
</tr>
<tr>
<td>No intervention</td>
<td>53% [BCD=41%;OCD=36%]</td>
</tr>
<tr>
<td>RRSO only at age 40</td>
<td>68% [BCD=45%;OCD=12%]</td>
</tr>
<tr>
<td>RRSO only at age 50</td>
<td>61% [BCD=51%;OCD=20%]</td>
</tr>
<tr>
<td>RRM only at age 25</td>
<td>66% [BCD=5%;OCD=58%]</td>
</tr>
<tr>
<td>RRM only at age 40</td>
<td>64% [BCD=13%;OCD=53%]</td>
</tr>
<tr>
<td>Breast screening only from ages 25–69</td>
<td>59% [BCD=26%;OCD=46%]</td>
</tr>
<tr>
<td>RRSO at age 40 and RRM at age 25</td>
<td>79% [BCD=6%;OCD=21%]</td>
</tr>
<tr>
<td>RRSO at age 40 and breast screening from ages 25–69</td>
<td>74% [BCD=30%;OCD=15%]</td>
</tr>
<tr>
<td>RRSO at age 40, RRM at age 40, and breast screening from ages 25–39</td>
<td>77% [BCD=18%;OCD=18%]</td>
</tr>
</tbody>
</table>

References


78. Chiu SY, Duffy S, Yen AM, et al. Effect of baseline breast density on breast cancer incidence, stage, mortality, and screening parameters: 25-year follow-up of a Swedish mammographic screening. Cancer Epidemiol...


184. Gray RG, Rea D, Handley K, et al. aTTom: Long-term effects of continuing adjuvant tamoxifen to 10 years versus stopping at 5 years in 6,953 women with early breast cancer. ASCO Meeting Abstracts 2013;31:5. Available at: http://meeting.ascpubs.org/cgi/content/abstract/31/18_suppl/5.


